Paediatric_JJAT JJATother
acute_JJAT JJATother
myeloid_NN NNother
leukaemia_NN NCOMP
with_IN INother
the_DT
t(_$
7;12_CD
)_-RRB-
(_-LRB-
q36;p13_NN NNother
)_-RRB-
rearrangement_NN NOMZ
:_:
a_DT
review_NN NNother
of_IN INother
the_DT
biological_JJAT JJATother
and_CC
clinical_JJAT JJATother
management_NN NNABSPROC
aspects_NN NCOMP
The_DT
presence_NN NNABSPROC
of_IN INother
chromosomal_JJAT JJATother
abnormalities_NN NOMZ
is_VPRT BEMA
one_CD
of_IN INother
the_DT
most_RB SUPER
important_JJAT JJATother
criteria_NN NNABSPROC
for_IN INother
leukaemia_NN NNother
diagnosis_NN NCOMP
and_CC
management_NN NNABSPROC
._.
Infant_NN NNHUMAN
leukaemia_NN NCOMP
is_VPRT BEMA
a_DT
rare_JJAT JJATother
disease_NN NNother
that_THRC THRCother
affects_VPRT CAUSE
children_NN NNHUMAN
in_IN INother
their_PP3t PP3all
first_JJAT JJATother
year_NN NNother
of_IN INother
life_NN NNABSPROC
._.
It_PIT
has_VPRT
been_PEAS
estimated_PASS PASSall
that_THSC THSCother
approximately_RB RBother
one_CD
third_NN NNother
of_IN INother
infants_NN NNHUMAN
with_IN INother
acute_JJAT JJATother
myeloid_NN NNother
leukaemia_NN NCOMP
harbour_NN NNother
the_DT
t(_$
7;12_CD
)_-RRB-
(_-LRB-
q36;p13_NN NNother
)_-RRB-
rearrangement_NN NOMZ
in_IN INother
their_PP3t PP3all
leukaemic_JJAT JJATother
blasts_NN NNother
._.
However_CC
,_,
the_DT
WHO_WHSC WHSCother
classification_NN NOMZ
of_IN INother
acute_JJAT JJATother
myeloid_NN NNother
leukaemia_NN NCOMP
does_VPRT SPLIT DOAUX
not_XX0
yet_TIME
include_VB EXIST
the_DT
t(_$
7;12_CD
)_-RRB-
as_IN INother
a_DT
separate_JJAT JJATother
entity_NN NOMZ
among_IN INother
the_DT
different_JJAT JJREL
genetic_JJAT JJATother
subtypes_NN NNother
,_,
although_CONC
the_DT
presence_NN NNABSPROC
of_IN INother
this_DEMO
chromosomal_JJAT JJATother
abnormality_NN NOMZ
has_VPRT
been_PEAS
associated_PASS PASSall
with_IN INother
an_DT
extremely_AMP
poor_JJAT JJEVAL
clinical_JJAT JJATother
outcome_NN NNother
._.
Currently_TIME
,_,
there_EX
is_VPRT
no_XX0
consensus_NN NNother
treatment_NN NCOMP
for_IN INother
t(_$
7;12_CD
)_-RRB-
leukaemia_NN NNother
patients_NN NCOMP
._.
However_CC
,_,
with_IN INother
the_DT
inferior_JJAT JJATother
outcome_NN NNother
with_IN INother
the_DT
standard_JJAT JJREL
induction_NN NOMZ
therapy_NN NCOMP
,_,
stem_NN NNCONC
cell_NN NCOMP
transplantation_NN NOMZ
may_MDMM MDPOSSCall
offer_VB COMM
a_DT
better_JJAT COMPAR
chance_NN NNother
for_IN INother
disease_NN NNother
control_NN NCOMP
._.
A_DT
better_JJAT COMPAR
insight_NN NNother
into_IN INother
the_DT
chromosome_NN NNTECH
biology_NN NCOMP
of_IN INother
this_DEMO
entity_NN NOMZ
might_MDMM MDPOSSCall
shed_VB
some_QUAN
light_NN NNTECH
into_IN INother
the_DT
pathogenic_JJAT JJATother
mechanisms_NN NNABSPROC
arising_VBG OCCUR
from_IN INother
this_DEMO
chromosomal_JJAT JJATother
translocation_NN NOMZ
,_,
that_THRC THRCother
at_IN INother
present_NN NNother
are_VPRT SPLIT
not_XX0
fully_AMP
understood_PASS PASSall MENTAL
._.
Further_JJAT COMPAR
work_NN NNABSPROC
is_VPRT
needed_PASS PASSall MENTAL
to_IN INother
improve_VB
our_PP1P PP1all
understanding_NN NNCOG
of_IN INother
the_DT
molecular_NN NNother
and_CC
genetic_JJAT JJATother
basis_NN NNother
of_IN INother
this_DEMO
disorder_NN NNABSPROC
._.
This_DEMO
will_MDWS MDPREDall SPLIT
open_VB ACT
some_QUAN
grounds_NN NNPLACE
for_IN PrepNSTNC
possible_JJPR JJEPSTother
tailored_VBN
treatment_NN NNABSPROC
for_IN INother
this_DEMO
subset_NN NNother
of_IN INother
very_AMP
young_JJAT JJTIME
patients_NN NNHUMAN
with_IN INother
inferior_JJAT JJATother
disease_NN NNother
outcome_NN NCOMP
._.
This_DEMO
review_NN NNother
aims_VPRT
at_IN INother
highlighting_VBG
the_DT
cytogenetic_JJAT JJATother
features_NN NNABSPROC
that_THRC THRCother
characterise_VPRT
the_DT
t(_$
7;12_CD
)_-RRB-
leukaemias_VPRT
for_IN INother
a_DT
better_JJAT COMPAR
detection_NN NOMZ
of_IN INother
the_DT
abnormality_NN NOMZ
in_IN INother
the_DT
diagnostic_JJAT JJATother
setting_NN NNABSPROC
._.
We_PP1P PP1all
also_CC
review_VB
treatment_NN NNABSPROC
and_CC
clinical_JJAT JJATother
outcome_NN NNother
in_IN INother
the_DT
cases_NN NNCONC
reported_VBN COMM
to_IN INother
date_NN NNQUANT
._.
Keywords_NN NNother
:_:
Acute_JJAT JJATother
myeloid_NN NNother
leukaemia_NN NCOMP
,_,
Paediatric_JJAT JJATother
leukaemia_NN NNother
,_,
t(_SYM
7;12_CD
)_-RRB-
translocation_NN NOMZ
,_,
Chromosomal_JJAT JJATother
abnormalities_NN NOMZ
,_,
HLXB9_NN NNother
gene_NN NCOMP
,_,
Clinical_JJAT JJATother
outcome_NN NNother
Introduction_NN NNP
Leukaemia_NN NNP
is_VPRT BEMA
the_DT
most_RB SUPER
common_JJAT JJATother
type_NN NNABSPROC
of_IN INother
cancer_NN NNother
in_IN INother
childhood_NN NNother
(_-LRB-
Fig._NN NNP
1_CD
)_-RRB-
._.
Among_IN INother
acute_JJAT JJATother
leukaemias_NN NNother
,_,
one_CD
in_IN INother
five_CD
is_VPRT
represented_PASS PASSall EXIST
by_IN INother
acute_JJAT JJATother
myeloid_NN NNother
leukaemia_NN NCOMP
(_-LRB-
AML_NN NNP
)_-RRB-
,_,
whereas_CONC
four_CD
fifths_NN NNother
are_VPRT BEMA
acute_JJAT JJATother
lymphoblastic_JJAT JJATother
leukaemia_NN NNother
(_-LRB-
ALL_QUAN
)_-RRB-
._.
Cancer_NN NNP
statistics_NN NCOMP
from_IN INother
the_DT
National_NN NNP
Registry_NN NNP
of_IN INother
Childhood_NN NNP
Tumours_NN NNP
show_VPRT ACT
a_DT
peak_NN NNCONC
at_IN INother
age_NN NNQUANT
2_CD
-_SYM
3_CD
years_NN NNother
for_IN INother
the_DT
insurgence_NN NNother
of_IN INother
ALL_QUAN
,_,
whereas_CONC
AML_NN NNP
is_VPRT BEMA
more_RB COMPAR
common_JJPR JJPRother
within_IN INother
the_DT
first_JJAT JJATother
year_NN NNother
of_IN INother
life_NN NNABSPROC
and_CC
after_IN INother
age_NN NNQUANT
10_CD
,_,
with_IN INother
an_DT
incidence_NN NNother
of_IN INother
16_CD
cases_NN NNCONC
per_IN INother
million_CD
in_IN INother
the_DT
United_NN NNP
Kingdom_NN NNP
._.
The_DT
incidence_NN NNother
of_IN INother
AML_NN NNP
decreases_VPRT
in_IN INother
children_NN NNHUMAN
older_JJPR COMPAR
than_IN INother
2_CD
years_NN NNother
of_IN INother
age_NN NNQUANT
,_,
but_CC
rises_VPRT OCCUR
in_IN INother
adolescence_NN NNother
when_WHSC WHSCother
it_PIT
stays_VPRT EXIST
stable_JJPR JJPRother
until_IN INother
adulthood_NN NNother
,_,
reaching_VBG ACT
its_PIT
peak_NN NNCONC
in_IN INother
older_JJAT COMPAR
individuals_NN NNHUMAN
[_-LRB-
1_CD
]_-RRB-
._.
Similar_JJAT JJREL
statistics_NN NNother
have_VPRT
been_PEAS
encountered_PASS PASSall ACT
in_IN INother
the_DT
populations_NN NOMZ
of_IN INother
the_DT
United_NN NNP
States_NN NNP
[_-LRB-
2_CD
,_,
3_CD
]_-RRB-
._.
In_IN INother
the_DT
past_JJAT JJATother
three_CD
decades_NN NNother
,_,
there_EX
has_VPRT
been_PEAS
a_DT
considerable_JJAT JJATother
improvement_NN NOMZ
in_IN INother
the_DT
cure_NN NNother
of_IN INother
childhood_NN NNother
leukaemia_NN NCOMP
,_,
reaching_VBG ACT
a_DT
long_JJAT JJDESCall JJSIZE
term_NN NNQUANT
survival_NN NCOMP
rate_NN NNQUANT
of_IN INother
more_QUAN
than_IN INother
90_CD
%_NN NNother
in_IN INother
ALL_QUAN
and_CC
approximately_RB RBother
70_CD
%_NN NNother
in_IN INother
AML_NN NNP
[_-LRB-
3_CD
,_,
4_CD
]_-RRB-
._.
However_CC
,_,
certain_JJAT JJEPSTother
categories_NN NNother
of_IN INother
childhood_NN NNother
leukaemia_NN NCOMP
are_VPRT SPLIT
still_RB RBother
considered_PASS PASSall MENTAL
high_JJAT JJATother
risk_NN NNABSPROC
,_,
and_CC
this_DEMO
level_NN NNABSPROC
of_IN INother
risk_NN NNABSPROC
is_VPRT
dictated_PASS PASSall
by_IN INother
the_DT
presence_NN NNABSPROC
of_IN INother
cytogenetic_JJAT JJATother
and_CC
molecular_JJAT JJATother
genetic_JJAT JJATother
markers_NN NNCONC
._.
The_DT
amended_VBN
world_NN NNother
health_NN NCOMP
organization_NN NNPLACE
(_-LRB-
WHO_WHSC WHSCother
)_-RRB-
leukaemia_NN NNother
classification_NN NCOMP
includes_VPRT EXIST
the_DT
most_RB SUPER
relevant_JJAT JJATother
chromosomal_JJAT JJATother
rearrangements_NN NOMZ
to_IN INother
allow_VB CAUSE
proper_JJAT JJATother
risk_NN NNABSPROC
stratification_NN NCOMP
of_IN INother
leukaemia_NN NNother
patients_NN NCOMP
[_-LRB-
5_CD
]_-RRB-
._.
To_IN INother
date_NN NNQUANT
,_,
the_DT
t(_-LRB-
7;12_CD
)_-RRB-
(_-LRB-
q36;p13_NN NNother
)_-RRB-
rearrangement_NN NOMZ
found_VBN VFCTother
in_IN INother
infant_NN NNHUMAN
AML_NN NNP
has_VPRT
not_XX0
been_PEAS
incorporated_PASS PASSall
in_IN INother
the_DT
WHO_WHSC WHSCother
classification_NN NOMZ
,_,
although_CONC
it_PIT
has_VPRT
been_PEAS
le_NN NNother
distributed_PASS PASSall
under_IN INother
the_DT
terms_NN NNQUANT
of_IN INother
the_DT
Creative_NN NNP
Commons_NN NNP
Attribution_NN NNP
License_NN NNP
which_WHSC WHSCother
permits_VPRT CAUSE
unrestricted_JJAT JJATother
use_NN NNABSPROC
,_,
distribution_NN NNABSPROC
,_,
and_CC
reproduction_NN NOMZ
in_IN INother
any_QUAN
medium_NN NNother
,_,
associated_VBN
with_IN INother
poor_JJAT JJEVAL
clinical_JJAT JJATother
outcome_NN NNother
[_-LRB-
3_CD
,_,
6_CD
]_-RRB-
._.
Fig._NN NNP
1_CD
Main_JJAT JJREL
types_NN NNABSPROC
of_IN INother
childhood_NN NNother
cancers_NN NCOMP
._.
The_DT
ideogram_NN NNother
shows_VPRT ACT
the_DT
different_JJAT JJREL
proportions_NN NOMZ
of_IN INother
cancers_NN NNother
affecting_VBG CAUSE
paediatric_JJAT JJATother
patients_NN NNHUMAN
._.
Acute_JJAT JJATother
leukaemia_NN NNother
is_VPRT BEMA
the_DT
most_RB SUPER
commonly_RB RBother
reported_VBN COMM
cancer_NN NNother
in_IN INother
children_NN NNHUMAN
,_,
with_IN INother
ALL_QUAN
affecting_VBG CAUSE
approximately_RB RBother
80_CD
%_NN NNother
of_IN INother
patients_NN NNHUMAN
and_CC
AML_NN NNother
diagnosed_VBN
in_IN INother
15_CD
-_SYM
20_CD
%_NN NNother
of_IN INother
patients_NN NNHUMAN
._.
Forms_NN NNother
of_IN INother
chronic_JJAT JJATother
leukaemia_NN NNother
and_CC
myelodysplastic_NN NNother
syndromes_NN NCOMP
are_VPRT BEMA
very_AMP
rare_JJPR JJPRother
in_IN INother
children_NN NNHUMAN
and_CC
their_PP3t PP3all
incidence_NN NNother
has_VPRT
been_PEAS
omitted_PASS PASSall
from_IN INother
this_DEMO
graph_NN NNTECH
(_-LRB-
based_VBN
on_IN INother
cancers_NN NNother
statistics_NN NCOMP
collected_VBN
from_IN INother
the_DT
National_NN NNP
Registry_NN NNP
of_IN INother
Childhood_NN NNP
Tumours_NN NNP
,_,
years_NN NNother
2009_CD
-_SYM
2011_CD
,_,
accessed_VBN
through_IN INother
the_DT
Cancer_NN NNP
Research_NN NNP
UK_NN NNP
website_NN NCOMP
)_-RRB-
This_DEMO
cytogenetic_JJAT JJATother
entity_NN NOMZ
has_VPRT
not_XX0
been_PEAS
associated_PASS PASSall
with_IN INother
a_DT
particular_JJAT JJREL
morphologic_JJPR JJPRother
or_CC
immunophenotypic_JJAT JJATother
subtype_NN NNother
[_-LRB-
6_CD
,_,
7_CD
]_-RRB-
,_,
but_CC
has_VPRT
been_PEAS
found_PASS PASSall
in_IN INother
a_DT
range_NN NNother
of_IN INother
AML_NN NNother
types_NN NCOMP
as_CC
well_RB RBother
as_IN INother
a_DT
case_NN NNCONC
of_IN INother
myelodysplastic_JJAT JJATother
syndrome_NN NNother
[_-LRB-
8_CD
]_-RRB-
._.
The_DT
scope_NN NNother
of_IN INother
this_DEMO
review_NN NNother
is_VPRT
to_IN INother
give_VB ACT
the_DT
reader_NN NNHUMAN
a_DT
comprehensive_JJAT JJATother
understanding_NN NNCOG
of_IN INother
the_DT
t(_$
7;12_CD
)_-RRB-
rearrangement_NN NOMZ
at_IN INother
the_DT
chromosomal_JJAT JJATother
level_NN NNABSPROC
and_CC
the_DT
available_JJAT JJATother
methods_NN NNABSPROC
for_IN INother
the_DT
detection_NN NOMZ
of_IN INother
this_DEMO
cytogenetic_JJAT JJATother
marker_NN NNCONC
for_IN INother
an_DT
improved_VBN
diagnosis_NN NNother
and_CC
a_DT
better_JJAT COMPAR
estimate_NN NNother
of_IN INother
the_DT
real_JJAT JJATother
incidence_NN NNother
of_IN INother
this_DEMO
type_NN NNABSPROC
of_IN INother
leukaemia_NN NNother
._.
We_PP1P PP1all
also_CC
review_VB
the_DT
clinical_JJAT JJATother
outcome_NN NNother
and_CC
the_DT
therapeutic_JJAT JJATother
approaches_NN NNABSPROC
that_THRC THRCother
have_VPRT
been_PEAS
adopted_PASS PASSall
in_IN INother
the_DT
cases_NN NNCONC
reported_VBN COMM
to_IN INother
date_NN NNQUANT
._.
Review_VIMP
The_DT
t(_NN NNother
7;12_CD
)_-RRB-
rearrangement_NN NOMZ
:_:
chromosomal_JJAT JJATother
appearance_NN NNother
and_CC
cytogenetic_JJAT JJATother
features_NN NNABSPROC
The_DT
t(_-LRB-
7;12_CD
)_-RRB-
rearrangement_NN NOMZ
typically_RB RSTNCall RNONFACT
involves_VPRT EXIST
the_DT
long_JJAT JJDESCall JJSIZE
arm_NN NNCONC
of_IN INother
chromosome_NN NNTECH
7_CD
at_IN INother
band_NN NNCONC
q36_NN NCOMP
and_CC
the_DT
short_JJAT JJDESCall JJSIZE
arm_NN NNCONC
of_IN INother
chromosome_NN NNTECH
12_CD
at_IN INother
band_NN NNCONC
p13_NN NCOMP
(_-LRB-
Fig._NN NNP
2_CD
)_-RRB-
._.
These_DEMO
chromosomal_JJAT JJATother
regions_NN NNPLACE
reside_VPRT
towards_IN INother
the_DT
end_NN NNABSPROC
of_IN INother
the_DT
chromosomes_NN NNTECH
,_,
near_PLACE
the_DT
telomeres_NN NNother
and_CC
involve_VPRT EXIST
fragments_NN NOMZ
of_IN INother
similar_JJAT JJREL
sizes_NN NNother
._.
The_DT
banding_NN NNother
patterns_NN NCOMP
of_IN INother
these_DEMO
subtelomeric_JJAT JJATother
regions_NN NNPLACE
are_VPRT
typically_RB RSTNCall RNONFACT
fairly_RB RBother
homogeneous_JJPR JJPRother
and_CC
not_XX0
distinctive_JJPR JJPRother
of_IN INother
a_DT
specific_JJAT JJATother
chromosome_NN NNTECH
._.
For_IN INother
these_DEMO
reasons_NN NSTNCother
the_DT
t(_$
7;12_CD
)_-RRB-
rearrangement_NN NOMZ
is_VPRT BEMA
a_DT
difficult_JJAT JJATother
cytogenetic_JJAT JJATother
entity_NN NOMZ
to_IN INother
detect_VB MENTAL
microscopically_RB RBother
,_,
using_VBG ACT
conventional_JJAT JJATother
methods_NN NNABSPROC
of_IN INother
chromosome_NN NNTECH
banding_NN NCOMP
._.
Nevertheless_CONC
,_,
early_JJAT JJTIME
reports_NN NSTNCother
demonstrate_VPRT VFCTother
identification_NN NOMZ
of_IN INother
t(_SYM
7;12_CD
)_-RRB-
based_VBN
on_IN INother
banding_NN NNother
analysis_NN NCOMP
only_RB RBother
[_-LRB-
9_CD
-_SYM
11_CD
]_-RRB-
._.
Furthermore_CC
,_,
the_DT
t(_NN NNother
7;12_CD
)_-RRB-
has_VPRT
been_PEAS
found_PASS PASSall
associated_VBN
with_IN INother
deletions_NN NOMZ
of_IN INother
the_DT
long_JJAT JJDESCall JJSIZE
arm_NN NNCONC
of_IN INother
chromosome_NN NNTECH
7_CD
,_,
therefore_RB CUZ
the_DT
der_NN NNP
(_-LRB-
7_CD
)_-RRB-
in_IN INother
these_DEMO
cases_NN NNCONC
might_MDMM MDPOSSCall
be_VB
misinterpreted_PASS PASSall
as_IN INother
a_DT
del_NN NNP
(_-LRB-
7q_NN NNP
)_-RRB-
._.
Fluorescence_NN NNother
in_IN INother
situ_FW
hybridisation_NN NOMZ
in_IN INother
one_CD
del_NN NNP
(_-LRB-
7_CD
)_-RRB-
(_-LRB-
q22_NN NNother
)_-RRB-
case_NN NNCONC
,_,
helped_VBD CAUSE
revising_VBG
this_DEMO
abnormality_NN NOMZ
as_IN INother
a_DT
der_NN NNP
(_-LRB-
7_CD
)_-RRB-
del_NN NNP
(_-LRB-
7_CD
)_-RRB-
(_-LRB-
q22q36_NN NNP
)_-RRB-
t(_-LRB-
7;12_CD
)_-RRB-
(_-LRB-
q22;p13_NN NNother
)_-RRB-
[_-LRB-
7_CD
,_,
8_CD
,_,
12_CD
]_-RRB-
._.
Translocation_NN NOMZ
breakpoints_NN NCOMP
In_IN INother
the_DT
t(_NN NNother
7;12_CD
)_-RRB-
(_-LRB-
q36;p13_NN NNother
)_-RRB-
,_,
the_DT
breakpoints_NN NNother
on_IN INother
chromosome_NN NNTECH
12_CD
are_VPRT BEMA
consistently_RB RBother
at_IN INother
the_DT
5_CD
′_NN NNother
end_NN NNABSPROC
of_IN INother
ETV6_NN NNP
,_,
between_IN INother
exons_NN NNother
1_CD
and_CC
3_CD
,_,
whereas_CONC
the_DT
breakpoints_NN NNother
on_IN INother
chromosome_NN NNTECH
7_CD
are_VPRT BEMA
quite_RB RBother
heterogeneous_JJPR JJPRother
affecting_VBG CAUSE
band_NN NNCONC
q36_NN NCOMP
in_IN INother
regions_NN NNPLACE
proximal_JJPR JJPRother
to_IN INother
the_DT
Homeobox_NN NNP
HB9_NN NNP
(_-LRB-
HLXB9_NN NNP
)_-RRB-
gene_NN NNTECH
[_-LRB-
6_CD
,_,
12_CD
,_,
13_CD
]_-RRB-
,_,
also_CC
known_VBN MENTAL
as_IN INother
MNX1_NN NNP
(_-LRB-
motor_NN NNCONC
neuron_NN NCOMP
and_CC
pancreas_NN NNother
homeobox_NN NCOMP
1_CD
)_-RRB-
._.
There_EX
have_VPRT
been_PEAS
descriptions_NN NNABSPROC
of_IN INother
breakpoints_NN NNother
in_IN INother
7q31_CD
[_-LRB-
10_CD
]_-RRB-
,_,
7q32_CD
[_-LRB-
14_CD
,_,
15_CD
]_-RRB-
,_,
and_CC
7q35_CD
-_SYM
36_CD
[_-LRB-
8_CD
]_-RRB-
._.
However_CC
,_,
some_QUAN
of_IN INother
these_DEMO
findings_NN NNother
were_VBD
not_XX0
validated_PASS PASSall
using_VBG ACT
fluorescence_NN NNother
in_IN INother
situ_FW
hybridisation_NN NOMZ
(_-LRB-
FISH_NN NNP
)_-RRB-
._.
Informative_JJAT JJATother
FISH_NN NNCONC
probes_NN NCOMP
spanning_VBG
7_CD
q_NN NNother
would_MDWO MDPREDall
have_VB
been_PEAS BEMA
helpful_JJPR JJPRother
towards_IN INother
achieving_VBG
a_DT
more_RB COMPAR
accurate_JJAT JJATother
definition_NN NNABSPROC
of_IN INother
the_DT
breakpoints_NN NNother
in_IN INother
these_DEMO
cases_NN NNCONC
._.
Cryptic_JJAT JJATother
and_CC
complex_JJAT JJATother
rearrangements_NN NOMZ
To_IN INother
date_NN NNQUANT
,_,
three_CD
cases_NN NNCONC
of_IN INother
complex_JJAT JJATother
rearrangements_NN NOMZ
harbouring_VBG
the_DT
t(_NN NNother
7;12_CD
)_-RRB-
have_VPRT
been_PEAS
reported_PASS PASSall COMM
[_-LRB-
16_CD
,_,
17_CD
]_-RRB-
._.
These_DEMO
three_CD
way_NN NNABSPROC
translocations_NN NCOMP
were_VBD
characterised_PASS PASSall
by_IN INother
FISH_NN NNP
and_CC
described_VBN COMM
as_IN INother
(_-LRB-
i_CD
)_-RRB-
t(_-LRB-
5;7;12_CD
)_-RRB-
(_-LRB-
q31;q36;p13_NN NNother
)_-RRB-
[_-LRB-
16_CD
]_-RRB-
;_:
(_-LRB-
ii_FPUH
)_-RRB-
t(_-LRB-
1;7;12_CD
)(_NN NNother
q25;q36;p13_NN NNother
)_-RRB-
[_-LRB-
16_CD
]_-RRB-
and_CC
(_-LRB-
iii_FPUH
)_-RRB-
t(_-LRB-
7;12;16_CD
)_-RRB-
(_-LRB-
q36;p13_NN NNother
;_:
q12_NN NNother
)_-RRB-
[_-LRB-
17_CD
]_-RRB-
respectively_RB RBother
._.
Due_IN INother
to_IN INother
the_DT
breakpoints_NN NNother
affecting_VBG CAUSE
the_DT
terminal_JJAT JJATother
regions_NN NNPLACE
of_IN INother
both_QUAN
chromosomes_NN NNTECH
7_CD
and_CC
12_CD
,_,
the_DT
t(_NN NNother
7;12_CD
)_-RRB-
(_-LRB-
q36;p13_NN NNother
)_-RRB-
is_VPRT
considered_PASS PASSall MENTAL
a_DT
cryptic_JJAT JJATother
rearrangement_NN NOMZ
._.
The_DT
use_NN NNABSPROC
of_IN INother
appropriate_JJAT JJATother
FISH_NN NNCONC
probes_NN NCOMP
would_MDWO MDPREDall SPLIT
surely_RB RBother
improve_VB
the_DT
detection_NN NOMZ
of_IN INother
this_DEMO
abnormality_NN NOMZ
and_CC
might_MDMM MDPOSSCall
uncover_VB
a_DT
higher_JJAT COMPAR
proportion_NN NOMZ
of_IN INother
t(_$
7;12_CD
)_-RRB-
translocations_NN NOMZ
masked_VBN
by_IN INother
more_RB COMPAR
complex_JJAT JJATother
rearrangements_NN NOMZ
,_,
as_IN INother
in_IN INother
the_DT
cases_NN NNCONC
of_IN INother
the_DT
three_CD
way_NN NNABSPROC
translocations_NN NCOMP
previously_TIME
described_VBN COMM
._.
Additional_JJAT JJREL
abnormalities_NN NOMZ
Interestingly_RB RBother
,_,
the_DT
majority_NN NOMZ
of_IN INother
t(_$
7;12_CD
)_-RRB-
cases_NN NNCONC
have_VPRT
been_PEAS
reported_PASS PASSall COMM
in_IN INother
association_NN NOMZ
with_IN INother
specific_JJAT JJATother
aneusomies_NN NNother
._.
A_DT
recent_JJAT JJTIME
review_NN NNother
of_IN INother
the_DT
literature_NN NNother
reported_VBD COMM
that_THSC ThSTNCall ThVSTNCall ThVCOMM
only_RB RBother
2_CD
out_IN INother
of_IN INother
44_CD
cases_NN NNCONC
harboured_VBD
the_DT
t(_NN NNother
7;12_CD
)_-RRB-
as_IN INother
a_DT
sole_JJAT JJATother
abnormality_NN NOMZ
[_-LRB-
17_CD
]_-RRB-
._.
In_IN INother
particular_JJPR ELAB
,_,
the_DT
presence_NN NNABSPROC
of_IN INother
one_CD
or_CC
more_RB COMPAR
additional_JJAT JJREL
copies_NN NNCONC
of_IN INother
chromosomes_NN NNTECH
8_CD
,_,
19_CD
and_CC
/_SYM
or_CC
22_CD
have_VPRT
been_PEAS SPLIT
recurrently_RB RBother
described_PASS PASSall COMM
[_-LRB-
6_CD
,_,
7_CD
,_,
15_CD
]_-RRB-
._.
Fig._NN NNP
2_CD
Schematic_JJAT JJATother
representation_NN NOMZ
of_IN INother
the_DT
t(_$
7;12_CD
)_-RRB-
(_-LRB-
q36;p13_NN NNother
)_-RRB-
and_CC
fusion_NN NNother
transcript_NN NCOMP
formation_NN NNABSPROC
._.
a_DT
Representation_NN NOMZ
of_IN INother
the_DT
7q36_CD
and_CC
12p13_CD
regions_NN NNPLACE
spanning_VBG
1_CD
Mb_NN NNother
around_IN INother
the_DT
genes_NN NNTECH
of_IN INother
interests_NN NNABSPROC
._.
The_DT
breakpoints_NN NNother
are_VPRT BEMA
proximal_JJPR JJPRother
to_IN INother
the_DT
HLXB9_NN NNP
gene_NN NCOMP
on_IN INother
chromosome_NN NNTECH
7_CD
and_CC
at_IN INother
the_DT
5_CD
′_NN NNother
end_NN NNABSPROC
of_IN INother
the_DT
ETV6_NN NNP
gene_NN NCOMP
on_IN INother
chromosome_NN NNTECH
12_CD
._.
HLXB9_NN NNP
is_VPRT BEMA
a_DT
small_JJAT JJDESCall JJSIZE
gene_NN NNTECH
composed_VBN
of_IN INother
three_CD
exons_NN NNother
._.
ETV6_NN NNP
is_VPRT BEMA
a_DT
larger_JJAT COMPAR
gene_NN NNTECH
composed_VBN
of_IN INother
eight_CD
exons_NN NNother
._.
In_IN INother
both_QUAN
cases_NN NNCONC
the_DT
direction_NN NNABSPROC
of_IN INother
transcription_NN NOMZ
is_VPRT BEMA
from_IN INother
the_DT
telomeric_NN NNother
to_IN INother
the_DT
centromeric_JJAT JJATother
end_NN NNABSPROC
._.
b_NN NNP
The_DT
gene_NN NNTECH
location_NN NCOMP
and_CC
direction_NN NNABSPROC
of_IN INother
transcription_NN NOMZ
of_IN INother
both_QUAN
HLXB9_NN NNP
and_CC
ETV6_NN NNP
are_VPRT
shown_PASS PASSall ACT
on_IN INother
the_DT
ideograms_NN NNother
of_IN INother
chromosomes_NN NNTECH
7_CD
and_CC
12_CD
._.
For_IN INother
each_QUAN
gene_NN NNTECH
all_QUAN
the_DT
exons_NN NNother
are_VPRT
indicated_PASS PASSall EXIST
._.
c_NN NNP
Derivative_JJAT JJATother
chromosomes_NN NNTECH
7_CD
and_CC
12_CD
:_:
the_DT
der_NN NNP
(_-LRB-
12_CD
)_-RRB-
harbours_VPRT
the_DT
whole_JJAT JJATother
HLXB9_NN NNother
gene_NN NCOMP
and_CC
the_DT
3′_JJAT JJATother
portion_NN NNQUANT
of_IN INother
ETV6_NN NNP
including_VBG EXIST
exons_NN NNother
3_CD
-_SYM
8_CD
._.
If_COND
a_DT
fusion_NN NNother
transcript_NN NCOMP
arose_VBD OCCUR
from_IN INother
this_DEMO
translocation_NN NOMZ
,_,
splicing_NN NNother
of_IN INother
HLXB9_NN NNother
exons_NN NCOMP
2_CD
and_CC
3_CD
as_CC
well_RB RBother
as_IN INother
any_QUAN
genomic_JJAT JJATother
material_NN NNother
from_IN INother
chromosome_NN NNTECH
7_CD
downstream_PLACE
to_IN INother
HLXB9_NN NNother
that_THRC THRCother
was_VBD
translocated_PASS PASSall
on_IN INother
the_DT
der_NN NNP
(_-LRB-
12_CD
)_-RRB-
should_MDNE
take_VB ACT
place_NN NNPLACE
The_DT
presence_NN NNABSPROC
of_IN INother
these_DEMO
additional_JJAT JJREL
abnormalities_NN NOMZ
has_VPRT
been_PEAS
reported_PASS PASSall COMM
in_IN INother
samples_NN NNTECH
at_IN INother
diagnosis_NN NNother
and_CC
/_,
or_CC
at_IN INother
relapse_NN NNother
,_,
indicating_VBG EXIST
that_THSC THSCother
the_DT
acquired_VBN ACT
aneusomies_NN NNother
might_MDMM MDPOSSCall
be_VB BEMA
sign_NN NNABSPROC
of_IN INother
clonal_JJAT JJATother
evolution_NN NNABSPROC
and_CC
important_JJPR JJPRother
for_IN INother
the_DT
establishment_NN NOMZ
and_CC
the_DT
survival_NN NNother
of_IN INother
the_DT
leukaemic_JJAT JJATother
clone_NN NNother
._.
Molecular_NN NNother
mechanisms_NN NCOMP
Is_VPRT
there_EX
a_DT
fusion_NN NNother
gene_NN NCOMP
?_. YNQU
A_DT
well_DMA
-_HYPH
established_VBN
driver_NN NNHUMAN
of_IN INother
haematological_JJAT JJATother
malignancy_NN NNother
when_WHSC WHSCother
a_DT
chromosomal_JJAT JJATother
translocation_NN NOMZ
is_VPRT BEMA
present_JJPR JJPRother
,_,
is_VPRT BEMA
the_DT
formation_NN NNABSPROC
of_IN INother
an_DT
oncogenic_JJAT JJATother
fusion_NN NNother
gene_NN NCOMP
such_JJPR JJPRother
as_IN ELAB
BCRABL_NN NNP
resulting_VBG
from_IN INother
the_DT
t(_NN NNother
9;22_CD
)_-RRB-
(_-LRB-
q34_NN NNother
;_:
q11_NN NNother
)_-RRB-
in_IN INother
chronic_JJAT JJATother
myeloid_NN NNother
leukaemia_NN NCOMP
or_CC
ETV6_NN NNP
-_HYPH
RUNX1_NN NNP
in_IN INother
t(_SYM
12;21_CD
)_-RRB-
(_-LRB-
p13;q22_NN NNother
)_-RRB-
positive_JJPR JJEPSTother
ALL_QUAN
[_-LRB-
18_CD
]_-RRB-
._.
As_IN INother
a_DT
consequence_NN CUZ
of_IN INother
these_DEMO
gene_NN NNTECH
fusions_NN NCOMP
,_,
a_DT
fusion_NN NNother
transcript_NN NCOMP
is_VPRT
produced_PASS PASSall ACT
with_IN INother
subsequent_JJAT JJATother
generation_NN NNABSPROC
of_IN INother
a_DT
chimeric_JJAT JJATother
protein_NN NNother
whose_WHSC WHSCother
altered_VBN
properties_NN NNPLACE
have_VPRT
an_DT
impact_NN NNABSPROC
on_IN INother
the_DT
onset_NN NNother
of_IN INother
the_DT
disease_NN NNother
._.
Reverse_JJAT JJATother
transcriptasepolymerase_NN NNother
chain_NN NCOMP
reaction_NN NNABSPROC
(_-LRB-
RT_NN NNP
-_HYPH
PCR_NN NNP
)_-RRB-
to_IN INother
identify_VB MENTAL
the_DT
fusion_NN NNother
transcript_NN NCOMP
in_IN INother
t(_SYM
7;12_CD
)_-RRB-
patients_NN NNHUMAN
showed_VBD ACT
a_DT
fusion_NN NNother
of_IN INother
exon_NN NNother
1_CD
of_IN INother
the_DT
HLXB9_NN NNP
gene_NN NCOMP
to_IN INother
either_CC
exons_NN NNother
2_CD
or_CC
3_CD
of_IN INother
the_DT
ETV6_NN NNP
gene_NN NCOMP
resulting_VBG
in_IN INother
two_CD
different_JJAT JJREL
HLXB9_NN NNP
-_HYPH
ETV6_NN NNP
fusion_NN NCOMP
transcripts_NN NNCONC
:_:
an_DT
out_IN INother
of_IN INother
frame_NN NNCONC
longer_JJAT COMPAR
variant_NN NNother
(_-LRB-
exon_NN NNother
1_CD
of_IN INother
HLXB9_NN NNP
to_IN INother
exon_NN NNP
Tosi_NN NNP
et_NN NNP
al_NN NNP
._.
Biomarker_NN NNP
Research_NN NNP
(_-LRB-
2015_CD
)_-RRB-
3:21_CD
Page_NN NNCONC
4_CD
of_IN INother
11_CD
2_CD
of_IN INother
ETV6_NN NNP
)_-RRB-
or_CC
an_DT
in_IN INother
-_HYPH
frame_NN NNCONC
shorter_JJAT COMPAR
variant_NN NNother
(_-LRB-
exon_NN NNother
1_CD
of_IN INother
HLXB9_NN NNP
to_IN INother
exon_NN NNother
3_CD
of_IN INother
ETV6_NN NNP
)_-RRB-
,_,
both_QUAN
fusion_NN NNother
transcripts_NN NCOMP
contain_VPRT EXIST
the_DT
first_JJAT JJATother
exon_NN NNother
of_IN INother
the_DT
HLXB9_NN NNother
gene_NN NCOMP
as_CC
well_RB RBother
as_IN INother
the_DT
ETS_NN NNother
domain_NN NCOMP
(_-LRB-
DNA_NN NNTECH
and_CC
protein_NN NNother
binding_NN NCOMP
domain_NN NNother
)_-RRB-
and_CC
the_DT
pointed_VBN
N_NN NNother
terminal_JJAT JJATother
domain_NN NNother
(_-LRB-
PNT_NN NNP
)_-RRB-
(_-LRB-
protein_NN NNother
-_HYPH
protein_NN NNother
binding_NN NCOMP
domain_NN NNother
)_-RRB-
of_IN INother
the_DT
ETV6_NN NNP
gene_NN NCOMP
[_-LRB-
6_CD
,_,
19_CD
-_SYM
21_CD
]_-RRB-
._.
However_CC
,_,
the_DT
presence_NN NNABSPROC
of_IN INother
an_DT
HLXB9_NN NNP
-_HYPH
ETV6_NN NNP
fusion_NN NCOMP
transcript_NN NNCONC
has_VPRT
been_PEAS
shown_PASS PASSall ACT
only_RB RBother
in_IN INother
approximately_RB RBother
50_CD
-_SYM
60_CD
%_NN NNother
of_IN INother
t(_$
7;12_CD
)_-RRB-
patients_NN NNHUMAN
reported_VBN COMM
to_IN INother
date_NN NNQUANT
(_-LRB-
Table_NN NNP
1_CD
)_-RRB-
,_,
whereas_CONC
the_DT
reciprocal_JJAT JJATother
ETV6_NN NNP
-_HYPH
HLXB9_NN NNP
transcript_NN NCOMP
has_VPRT SPLIT
never_FREQ
been_PEAS
observed_PASS PASSall MENTAL
._.
This_DEMO
is_VPRT BEMA
understandable_JJPR JJPRother
when_WHSC WHSCother
looking_VBG
at_IN INother
the_DT
details_NN NNABSPROC
of_IN INother
the_DT
translocation_NN NOMZ
breakpoints_NN NCOMP
at_IN INother
the_DT
chromosomal_JJAT JJATother
/_,
genomic_JJAT JJATother
level_NN NNABSPROC
._.
Although_CONC
the_DT
breakpoints_NN NNother
on_IN INother
chromosome_NN NNTECH
12_CD
are_VPRT SPLIT
well_RB RBother
defined_PASS PASSall EXIST
and_CC
disrupt_VB
the_DT
ETV6_NN NNP
gene_NN NCOMP
in_IN INother
a_DT
precise_JJAT JJATother
location_NN NNPLACE
at_IN INother
its_PIT
5_CD
′_NN NNother
end_NN NNABSPROC
,_,
on_IN INother
chromosome_NN NNTECH
7_CD
the_DT
breakpoints_NN NNother
are_VPRT
scattered_PASS PASSall
in_IN INother
different_JJAT JJREL
regions_NN NNPLACE
proximal_JJPR JJPRother
to_IN INother
the_DT
HLXB9_NN NNP
gene_NN NCOMP
._.
This_DEMO
implies_VPRT EXIST
that_THSC THSCother
the_DT
whole_JJAT JJATother
HLXB9_NN NNother
gene_NN NCOMP
is_VPRT
transferred_PASS PASSall
onto_IN INother
the_DT
der_NN NNP
(_-LRB-
12_CD
)_-RRB-
,_,
but_CC
there_EX
is_VPRT
no_XX0
disruption_NN NOMZ
of_IN INother
the_DT
gene_NN NNTECH
itself_PIT
._.
Moreover_CC
,_,
between_IN INother
HLXB9_NN NNP
and_CC
ETV6_NN NNP
on_IN INother
the_DT
der_NN NNP
(_-LRB-
12_CD
)_-RRB-
there_EX
should_MDNE
be_VB
genomic_JJAT JJATother
material_NN NNother
of_IN INother
variable_JJAT JJATother
extent_NN NNother
from_IN INother
7_CD
q_NN NNother
,_,
depending_VBG
on_IN INother
the_DT
location_NN NNPLACE
of_IN INother
the_DT
7_CD
q_NN NNother
breakpoint_NN NNother
(_-LRB-
Fig._NN NNother
2_CD
)_-RRB-
._.
This_DEMO
means_VPRT COMM
that_THSC ThSTNCall ThVSTNCall ThVFCT ThVCOMM
an_DT
HLXB9_NN NNP
-_HYPH
ETV6_NN NNP
fusion_NN NCOMP
transcript_NN NNCONC
would_MDWO MDPREDall
be_VB
generated_PASS PASSall
due_IN INother
to_IN INother
some_QUAN
form_NN NNother
of_IN INother
long_JJAT JJDESCall JJSIZE
range_NN NNother
splicing_NN NCOMP
._.
Depending_VBG
on_IN INother
how_WHSC WHSCother
efficient_JJPR JJPRother
this_DEMO
mechanism_NN NNABSPROC
is_VPRT
,_,
the_DT
fusion_NN NNother
transcript_NN NCOMP
might_MDMM MDPOSSCall
fail_VB
to_IN ToSTNCall ToVSTNCall ToVEFRT
be_VB BEMA
present_JJPR JJPRother
in_IN INother
all_QUAN
t(_-LRB-
7;12_CD
)_-RRB-
patients_NN NNHUMAN
._.
,_,
there_EX
has_VPRT
been_PEAS
no_XX0
report_NN NNother
on_IN PrepNSTNC
the_DT
presence_NN NNABSPROC
of_IN INother
a_DT
HLXB9_NN NNP
-_HYPH
ETV6_NN NNP
protein_NN NCOMP
to_IN INother
date_NN NNQUANT
,_,
therefore_RB CUZ
the_DT
production_NN NNABSPROC
of_IN INother
a_DT
chimeric_JJAT JJATother
protein_NN NNother
as_IN INother
an_DT
oncogenic_JJAT JJATother
trigger_NN NNother
for_IN INother
the_DT
t(_$
7;12_CD
)_-RRB-
leukaemias_NN NNother
is_VPRT BEMA
debatable_JJPR JJPRother
._.
HLXB9_VIMP
over_IN INother
-_HYPH
expression_NN NNABSPROC
As_IN INother
a_DT
fusion_NN NNother
transcript_NN NCOMP
is_VPRT
detected_PASS PASSall MENTAL
in_IN INother
only_RB RBother
approximately_RB RBother
fifty_CD
per_NN NNQUANT
cent_NN NCOMP
of_IN INother
t(_$
7;12_CD
)_-RRB-
AML_NN NNother
patients_NN NCOMP
,_,
it_PIT
is_VPRT BEMA
debatable_JJPR JJPRother
that_THSC THSCother
the_DT
formation_NN NNABSPROC
of_IN INother
the_DT
fusion_NN NNother
gene_NN NCOMP
is_VPRT BEMA
the_DT
only_JJAT JJATother
contributor_NN NNother
to_IN INother
leukaemogenesis_NN NNother
in_IN INother
these_DEMO
cases_NN NNCONC
._.
What_WHSC WHSCother
all_QUAN
the_DT
t(_$
7;12_CD
)_-RRB-
leukaemias_NN NNother
have_VPRT
in_IN INother
common_JJPR JJPRother
is_VPRT BEMA
the_DT
over_JJAT JJATother
-_HYPH
expression_NN NNABSPROC
of_IN INother
the_DT
Table_NN NNP
1_CD
Proportion_NN NOMZ
of_IN INother
patients_NN NNHUMAN
showing_VBG ACT
an_DT
HLXB9_NN NNP
-_HYPH
ETV6_NN NNP
fusion_NN NCOMP
transcript_NN NNCONC
No._NN NNother
of_IN INother
t(_$
7;12_CD
)_-RRB-
patients_NN NNHUMAN
considered_VBN MENTAL
No._NN NNother
of_IN INother
patients_NN NNHUMAN
with_IN INother
HLXB9_NN NNP
-_HYPH
ETV6_NN NNP
fusion_NN NCOMP
transcript_NN NNCONC
Percentage_NN NNQUANT
of_IN INother
patients_NN NNHUMAN
with_IN INother
HLXB9_NN NNP
-_HYPH
ETV6_NN NNP
fusion_NN NCOMP
transcript_NN NNCONC
Reference_NN NNother
2_CD
2_CD
100_CD
[_-LRB-
21_CD
]_-RRB-
7_CD
4_CD
57_CD
[_-LRB-
6_CD
]_-RRB-
2_CD
1_CD
50_CD
[_-LRB-
13_CD
]_-RRB-
1_CD
1_CD
100_CD
[_-LRB-
19_CD
]_-RRB-
7_CD
4_CD
57_CD
[_-LRB-
20_CD
]_-RRB-
6_CD
6_CD
100_CD
[_-LRB-
50_CD
]_-RRB-
Notes_NN NNCONC
:_:
The_DT
majority_NN NOMZ
of_IN INother
patients_NN NNHUMAN
considered_VBN MENTAL
in_IN INother
this_DEMO
table_NN NNCONC
were_VBD
reported_PASS PASSall COMM
as_IN INother
having_VBG
the_DT
t(_$
7;12_CD
)_-RRB-
in_IN INother
the_DT
karyotype_NN NNother
of_IN INother
their_PP3t PP3all
leukaemic_JJAT JJATother
cells_NN NNTECH
._.
However_CC
,_,
in_IN INother
4_CD
cases_NN NNCONC
[_-LRB-
13_CD
,_,
50_CD
,_,
56_CD
]_-RRB-
the_DT
fusion_NN NNother
transcript_NN NCOMP
was_VBD
described_PASS PASSall COMM
in_IN INother
patients_NN NNHUMAN
with_IN INother
abnormalities_NN NOMZ
of_IN INother
7q_NN NNother
and_CC
or_CC
12_CD
p_NN NNother
,_,
implying_VBG EXIST
that_THSC THSCother
the_DT
t(_NN NNother
7;12_CD
)_-RRB-
might_MDMM MDPOSSCall
have_VB
been_PEAS BEMA
present_JJPR JJPRother
,_,
but_CC
underestimated_VBN
in_IN INother
these_DEMO
cases_NN NNCONC
HLXB9_IN INother
gene_NN NNTECH
,_,
suggesting_VBG COMM
that_THSC ThSTNCall ThVSTNCall ThVCOMM
this_DEMO
,_,
rather_CC
than_IN INother
the_DT
formation_NN NNABSPROC
of_IN INother
a_DT
fusion_NN NNother
gene_NN NCOMP
,_,
might_MDMM MDPOSSCall
be_VB BEMA
the_DT
driver_NN NNHUMAN
of_IN INother
leukaemogenesis_NN NNother
in_IN INother
these_DEMO
patients_NN NNHUMAN
._.
Expression_NN NNABSPROC
of_IN INother
other_JJAT JJATother
genes_NN NNTECH
mapping_VBG
at_IN INother
7q36_CD
near_PLACE
the_DT
breakpoint_NN NNother
has_VPRT SPLIT
also_CC
been_PEAS
evaluated_PASS PASSall
and_CC
quantified_PASS PASSall
in_IN INother
t(_$
7;12_CD
)_-RRB-
patients_NN NNHUMAN
._.
However_CC
,_,
this_DEMO
analysis_NN NNCOG
showed_VBD ACT
that_DEMO
expression_NN NNABSPROC
of_IN INother
NOM1_NN NNP
,_,
LMBR1_NN NNP
and_CC
RNF32_NN NNP
in_IN INother
7q36_CD
as_CC
well_RB RBother
as_IN INother
ETV6_NN NNP
on_IN INother
12p13_CD
was_VBD BEMA
not_XX0
different_JJPR JJREL
from_IN INother
that_DEMO
observed_VBN MENTAL
in_IN INother
AML_NN NNP
patients_NN NCOMP
without_IN INother
the_DT
t(_$
7;12_CD
)_-RRB-
and_CC
in_IN INother
normal_JJAT JJATother
bone_NN NNCONC
marrow_NN NCOMP
[_-LRB-
6_CD
]_-RRB-
._.
The_DT
expression_NN NNABSPROC
of_IN INother
HLXB9_NN NNother
in_IN INother
healthy_JJAT JJATother
progenitor_NN NNother
blood_NN NCOMP
cells_NN NNTECH
in_IN INother
the_DT
bone_NN NNCONC
marrow_NN NCOMP
has_VPRT
been_PEAS
investigated_PASS PASSall
by_IN INother
several_QUAN
groups_NN NNother
._.
Early_JJAT JJTIME
expression_NN NNABSPROC
studies_NN NCOMP
performed_VBD
in_IN INother
1991_CD
showed_VBD ACT
that_THSC ThSTNCall ThVSTNCall ThVFCT
bone_NN NNCONC
marrow_NN NCOMP
enriched_VBN
for_IN INother
CD34_NN NNother
-_HYPH
positive_JJAT JJEPSTother
cells_NN NNTECH
highly_AMP
expressed_VBD COMM
HLXB9_NN NNP
,_,
whereas_CONC
unfractionated_JJAT JJATother
bone_NN NNCONC
marrow_NN NCOMP
cells_NN NNTECH
expressed_VBD COMM
HLXB9_NN NNother
in_IN INother
low_JJAT JJATother
levels_NN NNABSPROC
,_,
and_CC
bone_NN NNCONC
marrow_NN NCOMP
cells_NN NNTECH
depleted_VBN
of_IN INother
CD34_NN NNother
-_HYPH
positive_JJAT JJEPSTother
cells_NN NNTECH
did_VBD DOAUX
not_XX0
show_VB ACT
detectable_JJAT JJATother
levels_NN NNABSPROC
of_IN INother
HLXB9_NN NNother
[_-LRB-
22_CD
]_-RRB-
._.
Later_TIME
on_RB RBother
,_,
the_DT
same_JJAT JJREL
authors_NN NNHUMAN
reported_VBD COMM
increased_VBN OCCUR
levels_NN NNABSPROC
of_IN INother
HLXB9_NN NNother
expression_NN NCOMP
in_IN INother
acute_JJAT JJATother
leukaemias_NN NNother
that_THRC THRCother
were_VBD
not_XX0
seen_PASS PASSall MENTAL
in_IN INother
the_DT
leukaemia_NN NNother
patients_NN NCOMP
at_IN INother
remission_NN NNother
._.
These_DEMO
studies_NN NNABSPROC
suggested_VBD COMM
a_DT
link_NN NNABSPROC
between_IN INother
HLXB9_NN NNP
over_IN INother
-_HYPH
expression_NN NNABSPROC
and_CC
leukaemogenesis_NN NNother
[_-LRB-
23_CD
]_-RRB-
._.
Other_JJAT JJATother
authors_NN NNHUMAN
reported_VBD COMM
a_DT
relatively_RB RBother
low_JJAT JJATother
HLXB9_NN NNother
expression_NN NCOMP
in_IN INother
normal_JJAT JJATother
bone_NN NNCONC
marrow_NN NCOMP
by_IN INother
real_JJAT JJATother
time_NN NNQUANT
quantitative_JJAT JJATother
PCR_NN NNP
(_-LRB-
RT_NN NNP
-_HYPH
Q_NN NNP
-_HYPH
PCR_NN NNP
)_-RRB-
and_CC
did_VBD DOAUX
not_XX0
observe_VB MENTAL
HLXB9_NN NNother
expression_NN NCOMP
in_IN INother
healthy_JJAT JJATother
CD34_NN NNother
-_HYPH
positive_JJAT JJEPSTother
bone_NN NNCONC
marrow_NN NCOMP
cells_NN NNTECH
,_,
but_CC
described_VBD COMM
increased_VBN OCCUR
levels_NN NNABSPROC
in_IN INother
the_DT
bone_NN NNCONC
marrow_NN NCOMP
of_IN INother
leukaemia_NN NNother
patients_NN NCOMP
with_IN INother
the_DT
t(_$
7;12_CD
)_-RRB-
rearrangement_NN NOMZ
[_-LRB-
6_CD
,_,
24_CD
]_-RRB-
._.
Observations_NN NNCOG
from_IN PrepNSTNC
our_PP1P PP1all
group_NN NNother
and_CC
by_IN INother
others_NN NNother
confirmed_VBN MENTAL
elevated_VBN
HLXB9_NN NNP
expression_NN NCOMP
in_IN INother
t(_SYM
7;12_CD
)_-RRB-
leukaemias_NN NNother
as_CC
well_RB RBother
as_IN INother
in_IN INother
some_QUAN
patients_NN NNHUMAN
with_IN INother
acute_JJAT JJATother
myeloid_NN NNother
leukaemia_NN NCOMP
with_IN INother
chromosomal_JJAT JJATother
abnormalities_NN NOMZ
other_JJPR JJPRother
than_IN INother
the_DT
t(_NN NNother
7;12_CD
)_-RRB-
[_-LRB-
20_CD
,_,
25_CD
]_-RRB-
._.
HLXB9_NN NNother
expression_NN NCOMP
has_VPRT
been_PEAS
associated_PASS PASSall
with_IN INother
hypo_NN NNother
-_HYPH
methylation_NN NOMZ
of_IN INother
its_PIT
promoter_NN NNother
in_IN INother
a_DT
series_NN NNABSPROC
of_IN INother
paediatric_JJAT JJATother
AMLs_NN NNother
._.
However_CC
,_,
in_IN INother
the_DT
same_JJAT JJREL
study_NN NNABSPROC
it_PIT
was_VBD
found_PASS PASSall
that_THSC THSCother
in_IN INother
childhood_NN NNother
ALL_QUAN
the_DT
HLXB9_NN NNP
promoter_NN NCOMP
was_VBD BEMA
hyper_JJPR JJPRother
-_HYPH
methylated_VBN
leading_VBG
to_IN INother
down_IN INother
-_HYPH
regulation_NN NNABSPROC
of_IN INother
this_DEMO
gene_NN NNTECH
._.
The_DT
authors_NN NNHUMAN
suggest_VPRT COMM
that_THSC ThSTNCall ThVSTNCall ThVCOMM
HLXB9_NN NNP
might_MDMM MDPOSSCall
act_VB
as_IN INother
an_DT
oncogene_NN NNother
in_IN INother
AML_NN NNP
,_,
whereas_CONC
it_PIT
would_MDWO MDPREDall
act_VB
as_IN INother
a_DT
tumour_NN NNother
suppressor_NN NCOMP
gene_NN NNTECH
in_IN INother
ALL_QUAN
[_-LRB-
26_CD
]_-RRB-
._.
Over_IN INother
-_HYPH
expression_NN NNABSPROC
of_IN INother
HLXB9_NN NNP
has_VPRT
been_PEAS SPLIT
also_CC
reported_PASS PASSall COMM
in_IN INother
lymphoma_NN NNother
[_-LRB-
27_CD
,_,
28_CD
]_-RRB-
and_CC
cancer_NN NNother
types_NN NCOMP
other_JJPR JJPRother
than_IN INother
haematological_JJAT JJATother
malignancies_NN NNother
,_,
such_JJPR JJPRother
as_IN ELAB
breast_NN NNother
cancer_NN NCOMP
[_-LRB-
29_CD
]_-RRB-
,_,
testicular_JJAT JJATother
cancer_NN NNother
[_-LRB-
30_CD
,_,
31_CD
]_-RRB-
and_CC
hepatocarcinoma_NN NNother
[_-LRB-
32_CD
]_-RRB-
._.
These_DEMO
studies_NN NNABSPROC
support_VPRT
the_DT
idea_NN NSTNCother
that_THSC THSCother
HLXB9_JJAT JJATother
involvement_NN NOMZ
might_MDMM MDPOSSCall
be_VB BEMA
pivotal_JJPR JJPRother
in_IN INother
other_JJAT JJATother
tumours_NN NNother
as_CC
well_RB RBother
as_IN INother
leukaemia_NN NNother
._.
Limited_JJAT JJATother
studies_NN NNABSPROC
have_VPRT
been_PEAS
carried_PASS PASSall ACT
out_RP
on_IN INother
the_DT
HLXB9_NN NNP
expression_NN NCOMP
at_IN INother
the_DT
protein_NN NNother
level_NN NCOMP
,_,
whose_WHSC WHSCother
presence_NN NNABSPROC
has_VPRT
been_PEAS
demonstrated_PASS PASSall
in_IN INother
bone_NN NNCONC
marrow_NN NCOMP
smear_NN NNother
of_IN INother
leukaemia_NN NNother
patients_NN NCOMP
with_IN INother
the_DT
t(_NN NNother
7;12_CD
)_-RRB-
by_IN INother
immunohistochemistry_NN NNother
[_-LRB-
16_CD
]_-RRB-
._.
Further_JJAT COMPAR
studies_NN NNABSPROC
on_IN INother
leukaemia_NN NNother
as_CC
well_RB RBother
as_IN INother
other_JJAT JJATother
cancer_NN NNother
types_NN NCOMP
are_VPRT
needed_PASS PASSall MENTAL
in_IN INother
order_NN NNABSPROC
to_IN INother
clarify_VB
whether_WHSC WHSCother
the_DT
presence_NN NNABSPROC
of_IN INother
elevated_VBN
HLXB9_NN NNother
transcript_NN NCOMP
corresponds_VPRT
to_IN INother
proportionate_JJAT JJATother
levels_NN NNABSPROC
of_IN INother
the_DT
corresponding_VBG
protein_NN NNother
,_,
or_CC
whether_WHSC WHSCother
translation_NN NOMZ
is_VPRT
regulated_PASS PASSall
by_IN INother
RNA_NN NNP
interference_NN NCOMP
pathways_NN NNother
[_-LRB-
31_CD
]_-RRB-
._.
HLXB9_NN NNP
over_IN INother
-_HYPH
expression_NN NNABSPROC
and_CC
genome_NN NNother
organisation_NN NCOMP
An_DT
increasing_VBG OCCUR
number_NN NNQUANT
of_IN INother
studies_NN NNABSPROC
currently_TIME
focus_VPRT
on_IN INother
gene_NN NNTECH
expression_NN NCOMP
in_IN INother
the_DT
context_NN NNABSPROC
of_IN INother
the_DT
three_CD
dimensional_JJPR JJPRother
(_-LRB-
3D_NN NNother
)_-RRB-
genome_NN NNother
organisation_NN NCOMP
in_IN INother
the_DT
interphase_NN NNother
nucleus_NN NCOMP
[_-LRB-
33_CD
]_-RRB-
._.
Gene_NN NNP
positioning_NN NCOMP
within_IN INother
the_DT
different_JJAT JJREL
areas_NN NNPLACE
of_IN INother
the_DT
cell_NN NNTECH
nucleus_NN NCOMP
has_VPRT
been_PEAS
associated_PASS PASSall
with_IN INother
different_JJAT JJREL
levels_NN NNABSPROC
of_IN INother
gene_NN NNTECH
activity_NN NCOMP
,_,
with_IN INother
the_DT
general_JJAT JJREL
assumption_NN NSTNCother
that_THSC THSCother
transcriptionally_RB RBother
active_JJAT JJATother
genes_NN NNTECH
are_VPRT
localised_PASS PASSall
in_IN INother
the_DT
nuclear_JJAT JJATother
interior_NN NNPLACE
,_,
whereas_CONC
less_RB COMPAR
active_JJAT JJATother
genes_NN NNTECH
tend_VPRT EXIST
to_IN ToSTNCall ToVSTNCall ToVPROB
be_VB
positioned_PASS PASSall
towards_IN INother
the_DT
periphery_NN NNother
of_IN INother
the_DT
nucleus_NN NNTECH
[_-LRB-
34_CD
-_SYM
37_CD
]_-RRB-
._.
It_PIT
has_VPRT SPLIT
also_CC
been_PEAS
shown_PASS PASSall ACT
that_THSC THSCother
gene_NN NNTECH
positioning_NN NCOMP
in_IN INother
the_DT
nucleus_NN NNTECH
is_VPRT
not_XX0
fixed_PASS PASSall ACT
,_,
but_CC
may_MDMM MDPOSSCall
change_VB OCCUR
according_VBG
to_IN INother
different_JJAT JJREL
stages_NN NNABSPROC
of_IN INother
development_NN NNABSPROC
[_-LRB-
38_CD
,_,
39_CD
]_-RRB-
and_CC
in_IN INother
pathologies_NN NNother
[_-LRB-
40_CD
]_-RRB-
._.
It_PIT
has_VPRT
been_PEAS
demonstrated_PASS PASSall
that_THSC THSCother
the_DT
chromosome_NN NNTECH
3D_NN NCOMP
structure_NN NNABSPROC
within_IN INother
the_DT
interphase_NN NNother
nucleus_NN NCOMP
has_VPRT
an_DT
influence_NN NNABSPROC
on_IN INother
the_DT
transcriptional_JJAT JJATother
activities_NN NNABSPROC
of_IN INother
specific_JJAT JJATother
Fig._NN NNP
3_CD
Simplified_VBN
model_NN NNABSPROC
of_IN INother
radial_JJAT JJATother
chromosome_NN NNTECH
and_CC
gene_NN NNTECH
organisation_NN NCOMP
in_IN INother
th_NN NNP
gene_NN NCOMP
dense_JJAT JJATother
and_CC
gene_JJAT JJATother
poor_JJAT JJEVAL
bands_NN NNCONC
are_VPRT
arranged_PASS PASSall ACT
in_IN INother
a_DT
zig_NN NNother
-_HYPH
zag_NN NNother
manner_NN NCOMP
,_,
with_IN INother
the_DT
compact_JJAT JJATother
,_,
generally_FREQ
not_XX0
-_HYPH
transcribed_VBN
,_,
chromatin_NN NNother
organisation_NN NCOMP
._.
The_DT
gene_NN NNTECH
dense_JJPR JJPRother
r_VPRT
open_JJAT JJATother
chromatin_NN NNother
structure_NN NCOMP
,_,
that_THRC THRCother
favour_VPRT
gene_NN NNTECH
transcription_NN NCOMP
._.
The_DT
interaction_NN NOMZ
of_IN INother
ci_NN NNother
regulatory_JJAT JJATother
factors_NN NNABSPROC
consents_VPRT
gene_NN NNTECH
activation_NN NCOMP
._.
Upper_JJAT COMPAR
right_NN NSTNCother
:_:
a_DT
chromosomal_JJAT JJATother
transl_NN NNother
nucleus_NN NCOMP
could_MDCO MDPOSSCall
determine_VB MENTAL
an_DT
ectopic_JJAT JJATother
activation_NN NOMZ
of_IN INother
translocated_VBN
genes_NN NNTECH
,_,
on_IN INother
Bottom_JJAT JJATother
panel_NN NNother
:_:
Schematic_JJAT JJATother
representation_NN NOMZ
of_IN INother
the_DT
distribution_NN NNABSPROC
of_IN INother
FISH_NN NNCONC
signals_NN NCOMP
rela_NN NNother
of_IN INother
HLXB9_NN NNother
occupy_VPRT
a_DT
peripheral_JJAT JJATother
positioning_NN NNother
,_,
whereas_CONC
both_QUAN
copies_NN NNCONC
of_IN INother
ETV6_NN NNP
are_VPRT
lo_FW
HLXB9_NN NNother
gene_NN NCOMP
translocated_VBN
on_IN INother
the_DT
der_NN NNP
(_-LRB-
12_CD
)_-RRB-
is_VPRT
repositioned_PASS PASSall
towards_IN INother
the_DT
nuclear_NN NNother
in_IN INother
the_DT
der_NN NNP
(_-LRB-
7_CD
)_-RRB-
is_VPRT
repositioned_PASS PASSall
towards_IN INother
the_DT
nuclear_JJAT JJATother
periphery_NN NNother
genes_NN NCOMP
due_IN INother
to_IN INother
a_DT
position_NN NNABSPROC
effect_NN NCOMP
mechanism_NN NNABSPROC
._.
For_IN INother
instance_NN ELAB
,_,
gene_NN NNTECH
expression_NN NCOMP
at_IN INother
a_DT
specific_JJAT JJATother
locus_NN NNother
can_MDCA MDPOSSCall
be_VB
controlled_PASS PASSall ACT
in_IN INother
cis_NN NNother
by_IN INother
enhancer_NN NNother
elements_NN NCOMP
localised_VBN
at_IN INother
a_DT
distance_NN NNother
from_IN INother
it_PIT
,_,
via_IN INother
formation_NN NNABSPROC
of_IN INother
active_JJAT JJATother
chromatin_NN NNother
hubs_NN NCOMP
(_-LRB-
ACH_NN NNP
)_-RRB-
[_-LRB-
41_CD
-_SYM
43_CD
]_-RRB-
._.
Several_QUAN
studies_NN NNABSPROC
have_VPRT
been_PEAS
conducted_PASS PASSall
to_IN INother
observe_VB MENTAL
the_DT
behaviour_NN NNother
of_IN INother
cancer_NN NNother
loci_NN NCOMP
in_IN INother
the_DT
interphase_NN NNother
nuclei_NN NCOMP
using_VBG ACT
different_JJAT JJREL
cellular_JJAT JJATother
models_NN NNABSPROC
and_CC
some_QUAN
authors_NN NNHUMAN
proposed_VBD COMM
that_THSC ThSTNCall ThVSTNCall ThVCOMM
the_DT
altered_VBN
nuclear_JJAT JJATother
topography_NN NNother
of_IN INother
genes_NN NNTECH
could_MDCO MDPOSSCall
be_VB
used_PASS PASSall ACT
as_IN INother
diagnostic_JJAT JJATother
tool_NN NNCONC
in_IN INother
oncology_NN NNother
[_-LRB-
44_CD
,_,
45_CD
]_-RRB-
._.
Studies_NN NNABSPROC
on_IN INother
cancer_NN NNother
fusion_NN NCOMP
genes_NN NNTECH
have_VPRT
shown_PEAS ACT
nuclear_JJAT JJATother
repositioning_NN NNother
of_IN INother
chromosomes_NN NNTECH
and_CC
genes_NN NNTECH
after_IN INother
a_DT
translocation_NN NOMZ
event_NN NCOMP
[_-LRB-
46_CD
-_SYM
48_CD
]_-RRB-
and_CC
this_DEMO
repositioning_NN NNother
has_VPRT
been_PEAS
shown_PASS PASSall ACT
to_IN INother
have_VB
an_DT
impact_NN NNABSPROC
on_IN INother
expression_NN NNABSPROC
profiling_NN NCOMP
[_-LRB-
49_CD
]_-RRB-
._.
We_PP1P PP1all
have_VPRT
observed_PEAS MENTAL
the_DT
behaviour_NN NNother
of_IN INother
7q_CD
and_CC
12_CD
p_NN NNother
loci_NN NNother
in_IN INother
the_DT
interphase_NN NNother
nuclei_NN NCOMP
of_IN INother
leukaemia_NN NNother
cells_NN NCOMP
carrying_VBG ACT
the_DT
t(_$
7;12_CD
)_-RRB-
in_IN INother
a_DT
number_NN NNQUANT
of_IN INother
patients_NN NNHUMAN
and_CC
shown_VBN ACT
that_THSC ThSTNCall ThVSTNCall ThVFCT
the_DT
e_NN NNother
cell_NN NNTECH
nuclei_NN NCOMP
._.
Upper_JJPR COMPAR
left_VBN ACT
:_:
In_IN INother
the_DT
cell_NN NNTECH
nucleus_NN NCOMP
,_,
chromosomes_NN NNTECH
composed_VBN
of_IN INother
gene_NN NNTECH
poor_JJAT JJEVAL
regions_NN NNPLACE
(_-LRB-
blue_JJAT JJDESCall JJCOLR
segments_NN NOMZ
)_-RRB-
close_VPRT
to_IN INother
the_DT
nuclear_JJAT JJATother
envelope_NN NNCONC
,_,
in_IN INother
a_DT
egions_NN NNother
(_-LRB-
red_JJAT JJDESCall JJCOLR
segments_NN NOMZ
)_-RRB-
are_VPRT
located_PASS PASSall
in_IN INother
a_DT
more_RB COMPAR
internal_JJAT JJREL
position_NN NNABSPROC
,_,
with_IN INother
an_DT
s_NN NNother
-_HYPH
acting_NN NNother
or_CC
trans_JJPR JJPRother
-_HYPH
acting_NN NNother
sequences_NN NCOMP
,_,
as_CC
well_RB RBother
as_IN INother
the_DT
presence_NN NNABSPROC
of_IN INother
specific_JJAT JJATother
ocation_NN NOMZ
that_THRC THRCother
involves_VPRT EXIST
regions_NN NNPLACE
normally_FREQ
positioned_VBN
in_IN INother
different_JJAT JJREL
areas_NN NNPLACE
of_IN INother
the_DT
the_DT
basis_NN NNother
of_IN INother
the_DT
new_JJAT JJTIME
nuclear_JJAT JJATother
environment_NN NNPLACE
where_WHSC WHSCother
they_PP3t PP3all
are_VPRT
repositioned_PASS PASSall
._.
tive_VIMP
to_IN INother
the_DT
regions_NN NNPLACE
involved_VBN EXIST
in_IN INother
the_DT
t(_$
7;12_CD
)_-RRB-
rearrangement_NN NOMZ
._.
Left_VBN ACT
:_:
Both_QUAN
copies_NN NNCONC
calised_VBN
towards_IN INother
the_DT
interior_NN NNPLACE
in_IN INother
the_DT
nucleus_NN NNTECH
of_IN INother
normal_JJAT JJATother
cells_NN NNTECH
._.
Right_JJPR JJEPSTother
:_:
The_DT
terior_NN NNother
,_,
whereas_CONC
the_DT
remaining_VBG EXIST
portion_NN NNQUANT
of_IN INother
the_DT
ETV6_NN NNP
gene_NN NCOMP
translocated_VBD
on_IN INother
Tosi_NN NNP
et_NN NNP
al_NN NNP
._.
Biomarker_NN NNP
Research_NN NNP
(_-LRB-
2015_CD
)_-RRB-
3:21_CD
Page_NN NNCONC
6_CD
of_IN INother
11_CD
translocation_NN NOMZ
leads_VPRT
to_IN INother
repositioning_NN NNother
of_IN INother
the_DT
loci_NN NNother
of_IN INother
interest_NN NNABSPROC
(_-LRB-
Fig._NN NNP
3_CD
)_-RRB-
[_-LRB-
20_CD
]_-RRB-
._.
What_WHQU
does_VPRT DOAUX
this_DEMO
imply_VB EXIST
in_IN INother
terms_NN NNQUANT
of_IN INother
gene_NN NNTECH
transcription_NN NCOMP
?_. WQ
We_PP1P PP1all
have_VPRT
shown_PEAS ACT
the_DT
presence_NN NNABSPROC
of_IN INother
HLXB9_NN NNother
transcripts_NN NCOMP
in_IN INother
the_DT
same_JJAT JJREL
samples_NN NNTECH
with_IN INother
the_DT
t(_$
7;12_CD
)_-RRB-
rearrangement_NN NOMZ
by_IN INother
RT_NN NNP
-_HYPH
PCR_NN NNP
,_,
however_CC
,_,
we_PP1P PP1all
did_VBD DOAUX
not_XX0
investigate_VB
the_DT
origin_NN NNABSPROC
of_IN INother
the_DT
transcript_NN NNCONC
._.
We_PP1P PP1all
assume_VPRT MENTAL
that_THSC ThSTNCall ThVSTNCall ThVLIK
the_DT
nascent_JJAT JJATother
transcript_NN NNCONC
would_MDWO MDPREDall
originate_VB
from_IN INother
the_DT
der_NN NNP
(_-LRB-
12_CD
)_-RRB-
,_,
due_IN INother
to_IN INother
the_DT
juxtaposition_NN NOMZ
of_IN INother
the_DT
HLXB9_NN NNP
gene_NN NCOMP
to_IN INother
the_DT
downstream_PLACE
region_NN NNPLACE
of_IN INother
ETV6_NN NNP
._.
This_DEMO
would_MDWO MDPREDall
facilitate_VB
new_JJAT JJTIME
interactions_NN NOMZ
between_IN INother
active_JJAT JJATother
cis_JJAT JJATother
elements_NN NNTECH
and_CC
the_DT
HLXB9_NN NNP
promoter_NN NCOMP
,_,
leading_VBG
to_IN INother
the_DT
formation_NN NNABSPROC
of_IN INother
active_JJAT JJATother
chromatin_NN NNother
hubs_NN NCOMP
and_CC
repositioning_NN NNother
of_IN INother
the_DT
chromatin_NN NNother
in_IN INother
the_DT
cell_NN NNTECH
nucleus_NN NCOMP
._.
Alternatively_RB RBother
,_,
active_JJAT JJATother
trans_JJAT JJATother
sequences_NN NNother
from_IN INother
different_JJAT JJREL
chromosomes_NN NNTECH
could_MDCO MDPOSSCall
activate_VB
HLXB9_NN NNother
by_IN INother
a_DT
bridge_NN NNother
formation_NN NCOMP
in_IN INother
the_DT
new_JJAT JJTIME
nuclear_JJAT JJATother
environment_NN NNPLACE
._.
Gene_NN NNP
expression_NN NCOMP
signature_NN NNother
of_IN INother
t(_$
7;12_CD
)_-RRB-
leukaemias_NN NNother
and_CC
HLXB9_NN NNother
targets_NN NCOMP
The_DT
first_JJAT JJATother
study_NN NNABSPROC
to_IN INother
investigate_VB
expression_NN NNABSPROC
profiling_NN NCOMP
of_IN INother
t(_SYM
7;12_CD
)_-RRB-
leukaemias_NN NNother
was_VBD
conducted_PASS PASSall
by_IN INother
Wildenhain_NN NNP
et_NN NNP
al_NN NNP
._.
[_-LRB-
50_CD
]_-RRB-
,_,
who_WHSC WHSCother
compared_VBD MENTAL
leukaemic_JJAT JJATother
blasts_NN NNother
of_IN INother
patients_NN NNHUMAN
positive_JJPR JJEPSTother
for_IN INother
the_DT
presence_NN NNABSPROC
of_IN INother
the_DT
HLXB9_NN NNP
/_SYM
ETV6_NN NNP
fusion_NN NCOMP
transcript_NN NNCONC
with_IN INother
those_DEMO
with_IN INother
MLL_NN NNP
rearrangements_NN NCOMP
._.
It_PIT
has_MDNE
to_IN INother
be_VB
said_PASS PASSall COMM
that_THSC THSCother
these_DEMO
represent_VPRT EXIST
the_DT
two_CD
most_RB RBother
common_JJAT JJATother
chromosomal_JJAT JJATother
rearrangements_NN NOMZ
found_VBN VFCTother
in_IN INother
very_AMP
young_JJAT JJTIME
AML_NN NNother
patients_NN NCOMP
,_,
including_VBG EXIST
infants_NN NNHUMAN
and_CC
mainly_RB RSTNCall RNONFACT
children_NN NNHUMAN
younger_JJPR COMPAR
than_IN INother
2_CD
years_NN NNother
of_IN INother
age_NN NNQUANT
._.
The_DT
authors_NN NNHUMAN
found_VBD
that_THSC ThSTNCall ThVSTNCall ThVFCT
genes_NN NNTECH
expressed_VBN COMM
in_IN INother
the_DT
MLL_NN NNP
group_NN NCOMP
of_IN INother
patients_NN NNHUMAN
,_,
were_VBD
significantly_RB RBother
down_RB RBother
-_HYPH
regulated_VBN
in_IN INother
the_DT
HLXB9_NN NNother
/_,
ETV6_NN NNP
positive_JJAT JJEPSTother
patients_NN NNHUMAN
._.
These_DEMO
included_VBD EXIST
HOX_NN NNother
genes_NN NCOMP
and_CC
genes_NN NNTECH
characteristic_JJPR JJPRother
for_IN INother
the_DT
MLL_NN NNP
-_HYPH
induced_VBN
transformation_NN NOMZ
process_NN NCOMP
such_JJPR JJPRother
as_IN ELAB
MEIS1_NN NNP
,_,
HOXA9_NN NNP
and_CC
C_NN NNP
-_HYPH
MYB_NN NNP
._.
On_IN INother
the_DT
other_JJAT JJATother
hand_NN CC
,_,
together_RB RBother
with_IN INother
over_IN INother
-_HYPH
expression_NN NNABSPROC
of_IN INother
HLXB9_NN NNP
,_,
the_DT
HLXB9_NN NNP
/_SYM
ETV6_NN NNP
positive_JJAT JJEPSTother
patients_NN NNHUMAN
showed_VBD ACT
up_RP
-_HYPH
regulation_NN NNABSPROC
of_IN INother
genes_NN NNTECH
implicated_VBN
in_IN INother
cell_NN NNTECH
-_HYPH
cell_NN NNTECH
interactions_NN NCOMP
and_CC
cell_NN NNTECH
adhesion_NN NCOMP
such_JJPR JJPRother
as_IN ELAB
EDIL3_NN NNP
,_,
CNTNAP5_NN NNP
,_,
ANGPT1_NN NNP
,_,
DSG2_NN NNP
,_,
ITGA9_NN NNP
,_,
ITGAV_NN NNP
,_,
KDR_NN NNP
and_CC
SIGLEC6_NN NNP
._.
These_DEMO
are_VPRT
known_PASS PASSall MENTAL
to_IN INother
be_VB
implicated_PASS PASSall
in_IN INother
the_DT
maintenance_NN NNother
of_IN INother
quiescent_JJAT JJATother
haematopoietic_JJAT JJATother
stem_NN NNCONC
cells_NN NCOMP
(_-LRB-
HSC_NN NNP
)_-RRB-
and_CC
homeostasis_NN NNother
of_IN INother
the_DT
HSC_NN NNother
niche_NN NCOMP
._.
Overall_RB RBother
,_,
this_DEMO
study_NN NNABSPROC
implies_VPRT EXIST
that_THSC THSCother
the_DT
mechanisms_NN NNABSPROC
of_IN INother
leukaemogenesis_NN NNother
in_IN INother
these_DEMO
two_CD
types_NN NNABSPROC
of_IN INother
childhood_NN NNother
leukaemia_NN NCOMP
are_VPRT
fundamentally_RB RBother
very_AMP
different_JJPR JJREL
._.
Evidence_NN NNother
would_MDWO MDPREDall
suggest_VB COMM
that_THSC ThSTNCall ThVSTNCall ThVCOMM
the_DT
HLXB9_NN NNother
/_,
ETV6_NN NNP
positive_JJAT JJEPSTother
leukaemias_NN NNother
might_MDMM MDPOSSCall
be_VB
initiated_PASS PASSall
through_IN INother
an_DT
alterations_NN NOMZ
of_IN INother
interactions_NN NOMZ
between_IN INother
the_DT
HSC_NN NNother
and_CC
the_DT
HSC_NN NNother
niche_NN NCOMP
._.
Balgobind_NN NNP
et_FW
al._FW
[_-LRB-
51_CD
]_-RRB-
used_VBD ACT
expression_NN NNABSPROC
microarrays_NN NCOMP
to_IN INother
examine_VB MENTAL
a_DT
large_JJAT JJDESCall JJSIZE
cohort_NN NNother
of_IN INother
samples_NN NNTECH
from_IN INother
paediatric_JJAT JJATother
patients_NN NNHUMAN
with_IN INother
AML_NN NNP
including_VBG EXIST
seven_CD
samples_NN NNTECH
from_IN INother
patients_NN NNHUMAN
with_IN INother
the_DT
t(_$
7;12_CD
)_-RRB-
._.
The_DT
authors_NN NNHUMAN
built_VBD
a_DT
classifier_NN NNother
based_VBN
on_IN INother
59_CD
genes_NN NNTECH
that_THRC THRCother
enabled_VBD CAUSE
them_PP3t PP3all
to_IN INother
identify_VB MENTAL
very_AMP
specific_JJAT JJATother
expression_NN NNABSPROC
profiling_NN NCOMP
signatures_NN NNother
predictive_JJPR JJPRother
of_IN INother
cytogenetic_JJAT JJATother
and_CC
molecular_JJAT JJATother
subtypes_NN NNother
._.
This_DEMO
classification_NN NOMZ
tool_NN NCOMP
,_,
based_VBN
on_IN INother
the_DT
genetic_JJAT JJATother
heterogeneity_NN NOMZ
of_IN INother
paediatric_JJAT JJATother
AML_NN NNother
,_,
is_VPRT BEMA
of_IN INother
great_JJAT JJEVAL
diagnostic_JJAT JJATother
potential_NN NNABSPROC
although_CONC
its_PIT
feasibility_NN NOMZ
and_CC
implementation_NN NOMZ
in_IN INother
the_DT
diagnostic_JJAT JJATother
setting_NN NNABSPROC
will_MDWS MDPREDall
have_MDNE
to_IN INother
be_VB SPLIT
further_CC
explored_PASS PASSall ACT
._.
The_DT
significance_NN NNother
and_CC
the_DT
impact_NN NNABSPROC
of_IN INother
HLXB9_NN NNother
up_IN INother
-_HYPH
regulation_NN NNABSPROC
in_IN INother
the_DT
t(_$
7;12_CD
)_-RRB-
leukaemias_NN NNother
merits_VPRT
further_JJAT COMPAR
studies_NN NNABSPROC
._.
These_DEMO
would_MDWO MDPREDall
shed_VB
some_QUAN
light_NN NNTECH
on_IN INother
the_DT
pathways_NN NNother
triggered_VBN
by_IN INother
this_DEMO
chromosomal_JJAT JJATother
rearrangement_NN NOMZ
._.
The_DT
only_JJAT JJATother
report_NN NNother
to_IN PrepNSTNC
date_NN NNQUANT
to_IN INother
explore_VB ACT
possible_JJAT JJEPSTother
targets_NN NNCONC
for_IN INother
HB9_NN NNP
(_-LRB-
the_DT
transcription_NN NOMZ
factor_NN NCOMP
coded_VBN
by_IN INother
the_DT
HLXB9_NN NNP
gene_NN NCOMP
)_-RRB-
in_IN INother
haematopoietic_JJAT JJATother
cells_NN NNTECH
was_VBD
performed_PASS PASSall
on_IN INother
the_DT
HL_NN NNP
-_HYPH
60_CD
myeloid_NN NNother
cell_NN NCOMP
line_NN NNother
using_VBG ACT
ChiPon_NN NNP
-_HYPH
chip_NN NNother
and_CC
expression_NN NNABSPROC
profiling_NN NCOMP
analyses_NN NNCOG
[_-LRB-
24_CD
]_-RRB-
._.
This_DEMO
study_NN NNABSPROC
describes_VPRT COMM
binding_NN NNother
of_IN INother
HB9_NN NNP
to_IN INother
the_DT
prostaglandin_JJAT JJATother
E_NN NNP
receptor_NN NNother
2_CD
(_-LRB-
PGTER2_NN NNP
)_-RRB-
promoter_NN NNother
resulting_VBG
in_IN INother
downregulation_NN NOMZ
of_IN INother
PGTER2_NN NNother
and_CC
consequent_JJAT JJATother
reduction_NN NOMZ
of_IN INother
intracellular_JJAT JJATother
cAMP_NN NNother
level_NN NCOMP
._.
This_DEMO
down_IN INother
-_HYPH
regulatory_JJAT JJATother
effect_NN NNABSPROC
on_IN INother
PGTER2_NN NNP
expression_NN NCOMP
was_VBD SPLIT
also_CC
observed_PASS PASSall MENTAL
in_IN INother
t(_$
7;12_CD
)_-RRB-
patients_NN NNHUMAN
._.
Together_RB RBother
with_IN INother
repression_NN NNother
of_IN INother
PGTER2_NN NNP
,_,
Wildenhain_NN NNP
et_FW
al._FW
[_-LRB-
24_CD
]_-RRB-
,_,
found_VBD
that_THSC ThSTNCall ThVSTNCall ThVFCT
HLXB9_NN NNP
expression_NN NCOMP
in_IN INother
the_DT
HL60_NN NNP
cell_NN NCOMP
line_NN NNother
had_VBD
mostly_RB RBother
a_DT
down_IN INother
-_HYPH
regulatory_JJAT JJATother
effect_NN NNABSPROC
on_IN INother
other_JJAT JJATother
genes_NN NNTECH
,_,
particularly_RB RBother
ZYX_NN NNP
and_CC
ETS1_NN NNP
._.
Physiologically_RB RBother
,_,
expression_NN NNABSPROC
of_IN INother
PGTER2_NN NNP
modulates_VPRT
differentiation_NN NOMZ
of_IN INother
osteoclasts_NN NNother
._.
Upregulation_NN NNP
of_IN INother
PTGER2_NN NNP
has_VPRT
been_PEAS
shown_PASS PASSall ACT
in_IN INother
immature_JJAT JJATother
myeloid_NN NNother
precursors_NN NCOMP
._.
PTGER2_NN NNP
becomes_VPRT OCCUR
subsequently_TIME
down_RB RBother
-_HYPH
regulated_VBN
after_IN INother
the_DT
cells_NN NNTECH
have_VPRT
differentiated_PEAS
into_IN INother
osteoclasts_NN NNother
[_-LRB-
52_CD
]_-RRB-
._.
Further_JJAT COMPAR
work_NN NNABSPROC
is_VPRT
needed_PASS PASSall MENTAL
to_IN INother
clarify_VB
the_DT
implications_NN NOMZ
of_IN PrepNSTNC
PTGER2_NN NNother
down_IN INother
-_HYPH
regulation_NN NNABSPROC
on_IN INother
the_DT
bone_NN NNCONC
marrow_NN NCOMP
niche_NN NNother
and_CC
on_IN INother
the_DT
differentiation_NN NOMZ
of_IN INother
immature_JJPR JJPRother
pre_AFX
-_HYPH
leukaemic_JJAT JJATother
cells_NN NNTECH
._.
Diagnostic_JJAT JJATother
tools_NN NNCONC
Chromosome_NN NNP
banding_VBG
The_DT
t(_NN NNother
7;12_CD
)_-RRB-
(_-LRB-
q36;p13_NN NNother
)_-RRB-
rearrangement_NN NOMZ
affects_VPRT CAUSE
the_DT
subtelomeric_JJAT JJATother
regions_NN NNPLACE
of_IN INother
chromosomes_NN NNTECH
7_CD
and_CC
12_CD
respectively_RB RBother
._.
Due_IN INother
to_IN INother
the_DT
small_JJAT JJDESCall JJSIZE
size_NN NNother
of_IN INother
the_DT
genomic_JJAT JJATother
fragments_NN NOMZ
translocated_VBN
,_,
this_DEMO
rearrangement_NN NOMZ
is_VPRT BEMA
difficult_JJPR JJPRother
to_IN ToSTNCall ToJSTNCall ToJEASE
detect_VB MENTAL
using_VBG ACT
the_DT
conventional_JJAT JJATother
methods_NN NNABSPROC
of_IN INother
chromosome_NN NNTECH
banding_NN NCOMP
._.
Fluorescence_NN NNother
in_IN INother
situ_FW
hybridisation_NN NOMZ
Fluorescence_NN NNP
in_IN INother
situ_FW
hybridisation_NN NOMZ
(_-LRB-
FISH_NN NNP
)_-RRB-
has_VPRT
been_PEAS BEMA
fundamental_JJPR JJPRother
for_IN INother
the_DT
identification_NN NOMZ
of_IN INother
the_DT
t(_NN NNother
7;12_CD
)_-RRB-
as_IN INother
a_DT
nonrandom_JJAT JJATother
rearrangement_NN NOMZ
[_-LRB-
7_CD
]_-RRB-
._.
Initially_TIME
,_,
probes_NN NNother
covering_VBG ACT
the_DT
entire_JJAT JJREL
ETV6_NN NNP
gene_NN NCOMP
in_IN INother
conjunction_NN NOMZ
with_IN INother
7q36_CD
probes_NN NNother
have_VPRT
been_PEAS
used_PASS PASSall ACT
for_IN INother
the_DT
screening_NN NNother
of_IN INother
a_DT
relatively_RB RBother
large_JJAT JJDESCall JJSIZE
number_NN NNQUANT
of_IN INother
paediatric_JJAT JJATother
patients_NN NNHUMAN
._.
This_DEMO
screening_NN NNother
enabled_VBD CAUSE
us_PP1P PP1all
to_IN INother
estimate_VB
the_DT
incidence_NN NNother
of_IN INother
this_DEMO
translocation_NN NOMZ
of_IN INother
approximately_RB RBother
one_CD
third_NN NNother
of_IN INother
patients_NN NNHUMAN
with_IN INother
infant_NN NNHUMAN
leukaemia_NN NCOMP
[_-LRB-
7_CD
]_-RRB-
._.
It_PIT
has_MDNE
to_IN INother
be_VB
noted_PASS PASSall
that_THSC THSCother
the_DT
breakpoints_NN NNother
on_IN INother
7q36_CD
in_IN INother
the_DT
t(_NN NNother
7;12_CD
)_-RRB-
patients_NN NNHUMAN
were_VBD
found_PASS PASSall
to_IN INother
be_VB BEMA
heterogeneous_JJPR JJPRother
and_CC
generally_FREQ
proximal_JJPR JJPRother
to_IN INother
HLXB9_NN NNother
without_IN INother
disrupting_VBG
the_DT
gene_NN NNTECH
itself_PIT
[_-LRB-
12_CD
]_-RRB-
._.
A_DT
three_CD
colour_NN NNother
FISH_NN NCOMP
assay_NN NNother
with_IN INother
probes_NN NNother
flanking_VBG
the_DT
HLXB9_NN NNP
gene_NN NCOMP
was_VBD
developed_PASS PASSall OCCUR
specifically_RB RBother
for_IN INother
the_DT
detection_NN NOMZ
of_IN INother
the_DT
t(_NN NNother
7;12_CD
)_-RRB-
(_-LRB-
q36;p13_NN NNother
)_-RRB-
(_-LRB-
Fig._NN NNP
4_CD
)_-RRB-
._.
This_DEMO
assay_NN NNother
enabled_VBD CAUSE
us_PP1P PP1all
to_IN SPLIT
successfully_RB RBother
identify_VB MENTAL
cryptic_JJPR JJPRother
and_CC
more_RB COMPAR
complex_JJPR JJPRother
t(_-LRB-
7;12_CD
)_-RRB-
rearrangements_NN NOMZ
[_-LRB-
17_CD
]_-RRB-
._.
Commercially_RB RBother
available_JJAT JJATother
FISH_NN NNCONC
probes_NN NCOMP
for_IN INother
the_DT
detection_NN NOMZ
of_IN INother
the_DT
t(_$
12;21_CD
)_-RRB-
translocation_NN NOMZ
are_VPRT
also_CC
suitable_JJPR JJPRother
for_IN INother
the_DT
detection_NN NOMZ
of_IN INother
the_DT
t(_NN NNother
7;12_CD
)_-RRB-
,_,
where_WHSC WHSCother
a_DT
split_VBN
ETV6_NN NNP
signal_NN NCOMP
is_VPRT
found_PASS PASSall
on_IN INother
the_DT
der_NN NNP
(_-LRB-
7_CD
)_-RRB-
and_CC
on_IN INother
the_DT
der_NN NNP
(_-LRB-
12_CD
)_-RRB-
._.
Fig._NN NNP
4_CD
Fluorescence_NN NNother
in_IN INother
situ_NN NNother
hybridisation_NN NCOMP
(_-LRB-
FISH_NN NNP
)_-RRB-
performed_VBD
on_IN INother
metaphase_NN NNother
chromosomes_NN NCOMP
harbouring_VBG
the_DT
t(_NN NNother
7;12_CD
)(_NN NNother
q36;p13_NN NNother
)_-RRB-
._.
a_DT
FISH_NN NNCONC
using_VBG ACT
a_DT
three_CD
colour_NN NNother
approach_NN NCOMP
enables_VPRT CAUSE
the_DT
detection_NN NOMZ
of_IN INother
both_QUAN
normal_JJAT JJATother
chromosomes_NN NNTECH
7_CD
(_-LRB-
harbouring_VBG
only_RB RBother
blue_JJAT JJDESCall JJCOLR
hybridisation_NN NOMZ
signals_NN NCOMP
)_-RRB-
and_CC
12_CD
(_-LRB-
harbouring_VBG
green_JJAT JJDESCall JJCOLR
and_CC
orange_JJAT JJATother
fluorescent_JJAT JJATother
signals_NN NNABSPROC
)_-RRB-
and_CC
their_PP3t PP3all
derivatives_NN NNother
(_-LRB-
green_JJAT JJDESCall JJCOLR
signals_NN NNABSPROC
on_IN INother
the_DT
der_NN NNother
(_-LRB-
7_CD
)_-RRB-
and_CC
blue_JJAT JJDESCall JJCOLR
and_CC
orange_JJAT JJATother
signals_NN NNABSPROC
on_IN INother
the_DT
der_NN NNP
(_-LRB-
12_CD
)_-RRB-
)_-RRB-
._.
The_DT
DAPI_NN NNP
counterstaining_NN NCOMP
of_IN INother
the_DT
chromosomes_NN NNTECH
has_VPRT
been_PEAS
converted_PASS PASSall
into_IN INother
grey_JJAT JJDESCall JJCOLR
scale_NN NNother
to_IN INother
simulate_VB
a_DT
G_NN NNother
-_HYPH
banding_NN NNother
pattern_NN NCOMP
(_-LRB-
figure_NN NNother
taken_VBN ACT
from_IN INother
Naiel_NN NNP
et_FW
al._FW
,_,
2013_CD
[_-LRB-
17_CD
]_-RRB-
)_-RRB-
._.
b_NN NNP
Schematic_JJAT JJATother
representation_NN NOMZ
showing_VBG ACT
localisation_NN NOMZ
and_CC
colour_NN NNother
-_HYPH
code_NN NNABSPROC
of_IN INother
the_DT
FISH_NN NNCONC
probes_NN NCOMP
relative_RB RBother
to_IN INother
the_DT
three_CD
colour_NN NNother
probe_NN NCOMP
set_NN NNABSPROC
used_VBN ACT
._.
c_NN NNP
FISH_NN NNP
using_VBG ACT
a_DT
two_CD
colour_NN NNother
approach_NN NCOMP
enables_VPRT CAUSE
the_DT
detection_NN NOMZ
of_IN INother
both_QUAN
normal_JJAT JJATother
chromosomes_NN NNTECH
7_CD
(_-LRB-
harbouring_VBG
only_RB RBother
orange_JJAT JJATother
hybridisation_NN NOMZ
signals_NN NCOMP
)_-RRB-
and_CC
12_CD
(_-LRB-
harbouring_VBG
only_RB RBother
green_JJAT JJDESCall JJCOLR
fluorescent_JJAT JJATother
signals_NN NNABSPROC
)_-RRB-
and_CC
their_PP3t PP3all
derivatives_NN NNother
carrying_VBG ACT
orange_JJAT JJATother
and_CC
green_JJAT JJDESCall JJCOLR
fusion_NN NNother
signals_NN NCOMP
._.
d_NN NNP
Schematic_JJAT JJATother
representation_NN NOMZ
showing_VBG ACT
localisation_NN NOMZ
and_CC
colour_NN NNother
-_HYPH
code_NN NNABSPROC
of_IN INother
the_DT
FISH_NN NNCONC
probes_NN NCOMP
relative_RB RBother
to_IN INother
the_DT
two_CD
colour_NN NNother
probe_NN NCOMP
set_NN NNABSPROC
used_VBN ACT
._.
It_PIT
should_MDNE
be_VB
noted_PASS PASSall
that_THSC THSCother
the_DT
two_CD
colour_NN NNother
set_NN NCOMP
does_VPRT DOAUX
not_XX0
allow_VB CAUSE
to_IN ToSTNCall ToVSTNCall ToVEFRT
discriminate_VB
between_IN INother
the_DT
two_CD
derivatives_NN NNother
based_VBN
on_IN INother
colour_NN NNother
pattern_NN NCOMP
only_RB RBother
._.
The_DT
size_NN NNother
and_CC
morphology_NN NNother
of_IN INother
chromosomes_NN NNTECH
7_CD
and_CC
12_CD
compared_VBN MENTAL
to_IN INother
their_PP3t PP3all
respective_JJAT JJATother
derivatives_NN NNother
are_VPRT BEMA
very_AMP
similar_JJPR JJREL
,_,
making_VBG ACT
the_DT
identification_NN NOMZ
of_IN INother
the_DT
rearrangement_NN NOMZ
difficult_JJPR JJPRother
without_IN INother
the_DT
aid_NN NNABSPROC
of_IN INother
FISH_NN NNCONC
._.
Both_QUAN
probe_NN NNother
sets_NN NCOMP
have_VPRT
been_PEAS
provided_PASS PASSall ACT
by_IN INother
MetaSystems_NN NNP
Gmbh_NN NNP
,_,
Altlussheim_NN NNP
,_,
Germany_NN NNP
Dual_NN NNP
colour_NN NCOMP
whole_JJPR JJPRother
or_CC
partial_JJAT JJATother
chromosome_NN NNTECH
painting_NN NCOMP
may_MDMM MDPOSSCall SPLIT
also_CC
reveal_VB EXIST
the_DT
t(_NN NNother
7;12_CD
)_-RRB-
(_-LRB-
q36;p13_NN NNother
)_-RRB-
._.
However_CC
,_,
visualisation_NN NOMZ
of_IN INother
the_DT
rearrangement_NN NOMZ
on_IN INother
one_CD
or_CC
both_QUAN
derivatives_NN NNother
might_MDMM MDPOSSCall
be_VB
impaired_PASS PASSall
due_IN INother
to_IN INother
the_DT
small_JJAT JJDESCall JJSIZE
size_NN NNother
of_IN INother
the_DT
translocated_VBN
fragments_NN NOMZ
._.
Reverse_JJAT JJATother
transcription_NN NOMZ
polymerase_NN NCOMP
chain_NN NNCONC
reaction_NN NCOMP
Specific_JJAT JJATother
primers_NN NNother
have_VPRT
been_PEAS
designed_PASS PASSall
for_IN INother
the_DT
detection_NN NOMZ
of_IN INother
the_DT
HLXB9_NN NNP
/_SYM
ETV6_NN NNP
fusion_NN NCOMP
at_IN INother
the_DT
cDNA_NN NNother
level_NN NCOMP
by_IN INother
reverse_NN NNother
transcription_NN NCOMP
polymerase_NN NNother
chain_NN NCOMP
reaction_NN NNABSPROC
(_-LRB-
RT_NN NNP
-_HYPH
PCR_NN NNP
)_-RRB-
[_-LRB-
21_CD
]_-RRB-
._.
However_CC
,_,
the_DT
presence_NN NNABSPROC
of_IN INother
a_DT
fusion_NN NNother
transcript_NN NCOMP
by_IN INother
RT_NN NNP
-_HYPH
PCR_NN NNP
has_VPRT
been_PEAS
identified_PASS PASSall MENTAL
only_RB RBother
in_IN INother
approximately_RB RBother
50_CD
%_NN NNother
of_IN INother
t(_SYM
7,12_CD
)_-RRB-
leukaemia_NN NNother
patients_NN NCOMP
(_-LRB-
Table_NN NNP
1_CD
)_-RRB-
._.
For_IN INother
this_DEMO
reason_NN NSTNCother
RT_NN NNP
-_HYPH
PCR_NN NNP
does_VPRT DOAUX
not_XX0
represent_VB EXIST
a_DT
reliable_JJAT JJATother
method_NN NNABSPROC
for_IN INother
the_DT
detection_NN NOMZ
of_IN INother
the_DT
t(_$
7;12_CD
)_-RRB-
rearrangements_NN NOMZ
at_IN INother
diagnosis_NN NNother
._.
However_CC
,_,
in_IN INother
those_DEMO
patients_NN NNHUMAN
positive_JJPR JJEPSTother
for_IN INother
the_DT
HLXB9_NN NNP
/_SYM
ETV6_NN NNP
fusion_NN NCOMP
transcript_NN NNCONC
,_,
RT_NN NNP
-_HYPH
PCR_NN NNP
would_MDWO MDPREDall
prove_VB MENTAL
useful_JJPR JJPRother
for_IN INother
the_DT
monitoring_NN NNother
of_IN INother
minimal_JJAT JJATother
residual_JJAT JJATother
disease_NN NNother
[_-LRB-
53_CD
]_-RRB-
._.
Expression_NN NNABSPROC
profiling_NN NCOMP
Studies_NN NNP
based_VBN
on_IN INother
expression_NN NNABSPROC
microarrays_NN NCOMP
have_VPRT
shown_PEAS ACT
that_THSC THSCother
the_DT
leukaemic_JJAT JJATother
cells_NN NNTECH
of_IN INother
patients_NN NNHUMAN
carrying_VBG ACT
the_DT
t(_$
7;12_CD
)_-RRB-
have_VPRT
a_DT
distinctive_JJAT JJATother
expression_NN NNABSPROC
pattern_NN NCOMP
that_THRC THRCother
allows_VPRT CAUSE
to_IN ToSTNCall ToVSTNCall ToVEFRT
discriminate_VB
Table_NN NNCONC
2_CD
Summary_NN NNother
of_IN INother
reports_NN NNother
of_IN PrepNSTNC
t(_$
7;12_CD
)_-RRB-
leukaemias_NN NNother
with_IN INother
treatments_NN NNABSPROC
and_CC
clinical_JJAT JJATother
outcome_NN NNother
Reference_NN NCOMP
Study_NN NNABSPROC
group_NN NCOMP
No._NN NNother
of_IN INother
patients_NN NNHUMAN
CNS_NN NNP
status_NN NCOMP
Treatment_NN NNABSPROC
/_,
Course_NN NNother
/_,
Outcome_NN NNother
[_-LRB-
15_CD
]_-RRB-
DCLSG_NN NNP
/_,
POG_NN NNP
10_CD
5_CD
Treatment_NN NNP
N/S_NN NNP
6_CD
died_VBD OCCUR
of_IN INother
leukemia_NN NNother
1_CD
died_VBD OCCUR
of_IN INother
leukemia_NN NNother
and_CC
infection_NN NOMZ
1_CD
died_VBD OCCUR
of_IN INother
infection_NN NOMZ
1_CD
died_VBD OCCUR
of_IN INother
treatment_NN NNABSPROC
related_JJAT JJATother
toxicity_NN NOMZ
1_CD
alive_JJPR JJPRother
,_,
22_CD
months_NN NNQUANT
after_IN INother
BMT_NN NNP
in_IN INother
CR1_NN NNP
[_-LRB-
13_CD
]_-RRB-
CCG_NN NNP
2_CD
2_CD
1_CD
relapsed_VBN
in_IN INother
bone_NN NNCONC
marrow_NN NCOMP
with_IN INother
bilateral_JJAT JJATother
chloromas_NN NNother
on_IN INother
the_DT
hips_NN NNother
._.
Treated_VBN
with_IN INother
radiation_NN NOMZ
and_CC
BMT_NN NNP
,_,
but_CC
later_TIME
died_VBD OCCUR
due_IN INother
to_IN INother
disease_NN NNother
1_CD
relapsed_VBN
twice_RB RBother
,_,
treated_VBN
with_IN INother
BMT_NN NNP
,_,
alive_JJPR JJPRother
after_IN INother
2_CD
years_NN NNother
[_-LRB-
6_CD
]_-RRB-
DCOG_NN NNP
6_CD
N/S_NN NNP
Treatment_NN NNP
N/S_NN NNP
Median_NN NNP
EFS_NN NNP
:_:
9_CD
months_NN NNQUANT
3_CD
-_HYPH
year_NN NNother
EFS_NN NCOMP
:_:
0_CD
%_NN NNother
3_CD
-_HYPH
year_NN NNother
OS_NN NCOMP
:_:
0_CD
%_NN NNother
[_-LRB-
19_CD
]_-RRB-
Japan_NN NNP
1_CD
N/S_NN NNP
Alive_JJPR JJPRother
after_IN INother
5_CD
years_NN NNother
,_,
treated_VBN
with_IN INother
chemotherapy_NN NNother
only_RB RBother
[_-LRB-
16_CD
]_-RRB-
Korea_NN NNP
3_CD
N/S_NN NNP
1_CD
received_VBD ACT
cord_NN NNother
blood_NN NCOMP
transplantation_NN NOMZ
at_IN INother
11_CD
months_NN NNQUANT
,_,
relapsed_VBD
4_CD
months_NN NNQUANT
later_TIME
,_,
then_RB RBother
died_VBD OCCUR
at_IN INother
16_CD
months_NN NNQUANT
1_CD
died_VBD OCCUR
during_IN INother
induction_NN NOMZ
chemotherapy_NN NCOMP
from_IN INother
multiple_JJAT JJATother
organ_NN NNother
failure_NN NSTNCother NCOMP
1_CD
achieved_VBD
remission_NN NNother
,_,
but_CC
relapsed_VBD
at_IN INother
10_CD
months_NN NNQUANT
,_,
and_CC
died_VBD OCCUR
at_IN INother
16_CD
months_NN NNQUANT
[_-LRB-
56_CD
]_-RRB-
COG_NN NNother
8_CD
N/S_NN NNP
Treatment_NN NCOMP
N/S_NN NNother
3_CD
-_HYPH
year_NN NNother
EFS_NN NCOMP
:_:
14_CD
%_NN NNother
3_CD
-_HYPH
year_NN NNother
OS_NN NCOMP
:_:
28_CD
%_NN NNother
2_CD
of_IN INother
7_CD
evaluable_JJAT JJATother
patients_NN NNHUMAN
are_VPRT BEMA
alive_JJPR JJPRother
(_-LRB-
1_CD
after_IN INother
chemotherapy_NN NNother
,_,
1_CD
after_IN INother
BMT_NN NNP
)_-RRB-
(_-LRB-
personal_JJAT JJATother
communication_NN NOMZ
)_-RRB-
Notes_NN NNCONC
:_:
DCLSG_NN NNP
Dutch_NN NNP
Childhood_NN NNP
Leukemia_NN NNP
Study_NN NNP
Group_NN NNP
;_:
POG_NN NNP
Pediatric_NN NNP
Oncology_NN NNP
Group_NN NNP
;_:
CCG_NN NNP
Children_NN NNP
's_POS
Cancer_NN NNP
Group_NN NNP
;_:
COG_NN NNP
Children_NN NNP
Oncology_NN NNP
Group_NN NNP
;_:
DCOG_NN NNP
Dutch_NN NNP
Childhood_NN NNP
Oncology_NN NNP
Group_NN NNP
;_:
N/S_NN NNP
not_XX0
specified_VBN COMM
;_:
BMT_NN NNP
bone_NN NCOMP
marrow_NN NNother
transplantation_NN NCOMP
;_:
CR1_NN NNP
first_JJAT JJATother
complete_JJAT JJREL
remission_NN NNother
;_:
EFS_NN NNP
event_NN NCOMP
-_HYPH
free_JJAT JJATother
survival_NN NNother
;_:
OS_NN NNP
overall_JJAT JJATother
survival_NN NNother
Tosi_NN NNP
et_FW
al_NN NNP
._.
Biomarker_NN NNP
Research_NN NNP
(_-LRB-
2015_CD
)_-RRB-
3:21_CD
Page_NN NNCONC
8_CD
of_IN INother
11_CD
this_DEMO
specific_JJAT JJATother
cytogenetic_JJAT JJATother
subgroup_NN NNother
from_IN INother
other_JJPR JJPRother
[_-LRB-
51_CD
]_-RRB-
._.
Microarray_NN NNother
based_VBN
technologies_NN NNother
combined_VBN ACT
with_IN INother
appropriate_JJAT JJATother
classifiers_NN NNother
constitute_VPRT EXIST
potentially_RB RBother
a_DT
very_AMP
powerful_JJAT JJATother
diagnostic_JJAT JJATother
approach_NN NNABSPROC
,_,
although_CONC
in_IN INother
a_DT
routine_JJAT JJATother
diagnostic_JJAT JJATother
laboratory_NN NNGRP
the_DT
availability_NN NOMZ
of_IN INother
specialised_VBN
equipment_NN NNCONC
and_CC
costs_NN NNother
involved_VBN EXIST
might_MDMM MDPOSSCall
impact_VB
on_IN INother
the_DT
choice_NN NNABSPROC
of_IN INother
method_NN NNABSPROC
._.
Incidence_NN NNother
A_DT
literature_NN NNother
search_NN NCOMP
has_VPRT
shown_PEAS ACT
that_THSC THSCother
at_IN INother
least_JJAT JJATother
47_CD
leukaemia_NN NNother
patients_NN NCOMP
with_IN INother
the_DT
t(_NN NNother
7;12_CD
)_-RRB-
have_VPRT
been_PEAS
reported_PASS PASSall COMM
to_IN INother
date_NN NNQUANT
,_,
based_VBN
on_IN INother
the_DT
presence_NN NNABSPROC
of_IN INother
the_DT
chromosomal_JJAT JJATother
translocation_NN NOMZ
and_CC
/_SYM
or_CC
the_DT
fusion_NN NNother
transcript_NN NCOMP
[_-LRB-
17_CD
]_-RRB-
._.
To_IN INother
date_NN NNQUANT
,_,
there_EX
are_VPRT
a_DT
very_AMP
limited_JJAT JJATother
number_NN NNQUANT
of_IN INother
studies_NN NNABSPROC
to_IN INother
address_VB COMM
the_DT
incidence_NN NNother
of_IN INother
this_DEMO
translocation_NN NOMZ
,_,
with_IN INother
a_DT
quite_RB RBother
comprehensive_JJAT JJATother
investigation_NN NOMZ
considering_VBG MENTAL
a_DT
total_NN NNother
of_IN INother
345_CD
paediatric_JJAT JJATother
patients_NN NNHUMAN
[_-LRB-
6_CD
]_-RRB-
._.
In_IN INother
this_DEMO
study_NN NNABSPROC
,_,
patients_NN NNHUMAN
were_VBD
subdivided_PASS PASSall
in_IN INother
289_CD
ALL_QUAN
,_,
of_IN INother
which_WHSC WHSCother
99_CD
were_VBD BEMA
infants_NN NNHUMAN
,_,
and_CC
59_CD
AML_NN NNother
,_,
of_IN INother
which_WHSC WHSCother
18_CD
were_VBD BEMA
infants_NN NNHUMAN
._.
It_PIT
emerged_VBD OCCUR
that_THSC THSCother
5_CD
out_IN INother
of_IN INother
18_CD
infant_NN NNHUMAN
AMLs_NN NNP
(_-LRB-
age_NN NNQUANT
0_CD
-_SYM
12_CD
months_NN NNQUANT
)_-RRB-
harboured_VBD
the_DT
t(_$
7;12_CD
)_-RRB-
rearrangement_NN NOMZ
,_,
making_VBG ACT
the_DT
incidence_NN NNother
of_IN INother
this_DEMO
rearrangement_NN NOMZ
near_PLACE
one_CD
third_NN NNother
of_IN INother
infant_NN NNHUMAN
AML_NN NCOMP
._.
In_IN INother
addition_NN CC
to_IN INother
the_DT
above_NN NNother
,_,
the_DT
t(_NN NNother
7;12_CD
)_-RRB-
was_VBD SPLIT
also_CC
found_PASS PASSall
in_IN INother
one_CD
infant_NN NNHUMAN
with_IN INother
ALL_QUAN
and_CC
one_CD
18_CD
month_NN NNQUANT
old_JJAT JJTIME
child_NN NNHUMAN
with_IN INother
AML_NN NNP
._.
A_DT
previous_JJAT JJREL
study_NN NNABSPROC
was_VBD
conducted_PASS PASSall
on_IN INother
a_DT
more_RB RBother
selected_VBN
series_NN NNABSPROC
of_IN INother
leukaemia_NN NNother
patients_NN NCOMP
,_,
chosen_VBN MENTAL
on_IN INother
the_DT
basis_NN NNother
of_IN INother
age_NN NNQUANT
<_-LRB-
20_CD
months_NN NNQUANT
and_CC
the_DT
presence_NN NNABSPROC
of_IN INother
additional_JJAT JJREL
copies_NN NNCONC
of_IN INother
chromosomes_NN NNTECH
8_CD
and_CC
/_,
or_CC
19_CD
,_,
as_CC
well_RB RBother
as_IN INother
abnormalities_NN NOMZ
of_IN INother
7q_NN NNother
and_CC
/_,
or_CC
12_CD
p_NN NNother
[_-LRB-
7_CD
]_-RRB-
._.
This_DEMO
study_NN NNABSPROC
showed_VBD ACT
that_THSC ThSTNCall ThVSTNCall ThVFCT
10_CD
out_IN INother
of_IN INother
23_CD
patients_NN NNHUMAN
harboured_VBD
a_DT
translocation_NN NOMZ
between_IN INother
7q_CD
and_CC
12_CD
p_NN NNother
._.
However_CC
,_,
in_IN INother
only_RB RBother
7_CD
cases_NN NNCONC
ETV6_NN NNP
was_VBD
involved_PASS PASSall EXIST
in_IN INother
the_DT
translocation_NN NOMZ
and_CC
of_IN INother
these_DEMO
,_,
6_CD
cases_NN NNCONC
had_VBD
breakpoint_NN NNother
in_IN INother
7q36_CD
and_CC
one_CD
in_IN INother
7q22_CD
._.
Later_TIME
studies_NN NNABSPROC
confirmed_VBD MENTAL
that_THSC THSCother
the_DT
incidence_NN NNother
of_IN INother
t(_NN NNP
7;12_CD
)_-RRB-
(_-LRB-
q36;p13_NN NNother
)_-RRB-
was_VBD BEMA
low_JJPR JJPRother
when_WHSC WHSCother
considering_VBG MENTAL
AML_NN NNP
paediatric_JJAT JJATother
patients_NN NNHUMAN
enrolled_VBN
for_IN INother
clinical_JJAT JJATother
trials_NN NNABSPROC
._.
These_DEMO
studies_NN NNABSPROC
reported_VBD COMM
four_CD
t(_SYM
7;12_CD
)_-RRB-
cases_NN NNCONC
out_IN INother
of_IN INother
729_CD
enrolled_VBN
in_IN INother
the_DT
UK_NN NNP
MRC_NN NNP
AML10_NN NNP
and_CC
AML_NN NNP
12_CD
;_:
one_CD
case_NN NNCONC
out_IN INother
of_IN INother
454_CD
in_IN INother
AML_NN NNP
-_HYPH
BFM_NN NNP
98_CD
and_CC
8_CD
cases_NN NNCONC
out_IN INother
of_IN INother
981_CD
enrolled_VBN
in_IN INother
the_DT
COG_NN NNP
trial_NN NCOMP
AAML0531_NN NNP
[_-LRB-
54_CD
-_SYM
56_CD
]_-RRB-
._.
Prognostic_JJAT JJATother
significance_NN NNother
and_CC
treatment_NN NNABSPROC
options_NN NCOMP
Prognostic_JJAT JJATother
significance_NN NNother
and_CC
clinical_JJAT JJATother
outcome_NN NNother
Cytogenetic_JJAT JJATother
and_CC
molecular_JJAT JJATother
markers_NN NNCONC
are_VPRT BEMA
important_JJAT JJATother
factors_NN NNABSPROC
to_IN INother
be_VB
taken_PASS PASSall ACT
in_IN INother
consideration_NN NNCOG
when_WHSC WHSCother
stratifying_VBG
patients_NN NNHUMAN
into_IN INother
high_JJAT JJATother
risk_NN NNABSPROC
/_,
low_JJAT JJATother
risk_NN NNABSPROC
categories_NN NCOMP
and_CC
are_VPRT BEMA
of_IN INother
guidance_NN NNother
for_IN INother
making_VBG ACT
treatment_NN NNABSPROC
choices_NN NCOMP
._.
The_DT
WHO_WHSC WHSCother
system_NN NNABSPROC
for_IN INother
the_DT
classification_NN NOMZ
of_IN INother
myeloid_NN NNother
neoplasms_NN NCOMP
and_CC
acute_JJAT JJATother
leukemia_NN NNother
has_VPRT
been_PEAS
amended_PASS PASSall
to_IN INother
include_VB EXIST
such_JJAT JJATother
information_NN NNABSPROC
[_-LRB-
5_CD
]_-RRB-
._.
At_IN INother
present_JJPR JJPRother
,_,
the_DT
t(_NN NNother
7;12_CD
)_-RRB-
(_-LRB-
q36;p13_NN NNother
)_-RRB-
is_VPRT
not_XX0
included_PASS PASSall EXIST
in_IN INother
the_DT
WHO_WHSC WHSCother
classification_NN NOMZ
,_,
although_CONC
it_PIT
is_VPRT
recommended_PASS PASSall COMM
that_THSC THSCother
it_PIT
be_VB
considered_PASS PASSall MENTAL
as_IN INother
a_DT
separate_JJAT JJATother
entity_NN NOMZ
when_WHSC WHSCother
assessing_VBG MENTAL
infant_NN NNHUMAN
leukaemia_NN NCOMP
[_-LRB-
3_CD
]_-RRB-
._.
Review_NN NNother
of_IN INother
published_VBN
data_NN NNTECH
on_IN INother
the_DT
clinical_JJAT JJATother
outcome_NN NNother
of_IN INother
the_DT
t(_NN NNother
7;12_CD
)_-RRB-
AMLs_NN NNP
reveals_VPRT EXIST
inferior_JJAT JJATother
outcome_NN NNother
with_IN INother
3_CD
years_NN NNother
probabilities_NN NCOMP
of_IN INother
event_NN NNother
free_JJAT JJATother
survival_NN NNother
(_-LRB-
EFS_NN NNP
)_-RRB-
of_IN INother
0_CD
-_SYM
14_CD
%_NN NNother
and_CC
overall_JJAT JJATother
survival_NN NNother
(_-LRB-
OS_NN NNP
)_-RRB-
of_IN INother
0_CD
-_SYM
28_CD
%_NN NNother
(_-LRB-
Table_NN NNP
2_CD
)_-RRB-
[_-LRB-
6_CD
,_,
13_CD
,_,
14_CD
,_,
16_CD
,_,
56_CD
]_-RRB-
._.
However_CC
,_,
one_CD
report_NN NNother
of_IN PrepNSTNC
a_DT
paediatric_JJAT JJATother
patient_NN NNHUMAN
with_IN INother
acute_JJAT JJATother
megakaryocytic_JJAT JJATother
leukaemia_NN NNother
and_CC
t(_SYM
7;12_CD
)_-RRB-
described_VBD COMM
achievement_NN NNABSPROC
of_IN INother
complete_JJAT JJREL
remission_NN NNother
with_IN INother
chemotherapy_NN NNother
alone_RB RBother
for_IN INother
60_CD
months_NN NNQUANT
at_IN INother
time_NN NNQUANT
of_IN INother
publication_NN NOMZ
[_-LRB-
19_CD
]_-RRB-
._.
Papers_NN NNCONC
from_IN INother
different_JJAT JJREL
clinical_JJAT JJATother
trial_NN NNABSPROC
groups_NN NCOMP
such_JJPR JJPRother
as_IN ELAB
the_DT
Children_NN NNP
's_POS
Oncology_NN NNP
Group_NN NNP
(_-LRB-
COG_NN NNP
)_-RRB-
[_-LRB-
56_CD
]_-RRB-
,_,
UK_NN NNP
MRC_NN NNP
AML_NN NNP
10_CD
and_CC
12_CD
[_-LRB-
53_CD
]_-RRB-
and_CC
the_DT
Berlin_NN NNP
-_HYPH
Frankfurt_NN NNP
-_HYPH
Munich_NN NNP
(_-LRB-
BFM_NN NNP
)_-RRB-
[_-LRB-
55_CD
]_-RRB-
included_VBD EXIST
the_DT
t(_NN NNother
7;12_CD
)_-RRB-
(_-LRB-
q36;p13_NN NNother
)_-RRB-
in_IN INother
the_DT
group_NN NNother
of_IN INother
patients_NN NNHUMAN
with_IN INother
12_CD
p_NN NNother
abnormalities_NN NOMZ
and_CC
confirmed_VBD MENTAL
their_PP3t PP3all
association_NN NOMZ
with_IN INother
poor_JJAT JJEVAL
prognosis_NN NNother
._.
It_PIT
was_VBD SPLIT
also_CC
stressed_PASS PASSall
the_DT
need_NN NNCOG
to_IN INother
Tosi_NN NNP
et_NN NNP
al_NN NNP
._.
Biomarker_NN NNP
Research_NN NNP
(_-LRB-
2015_CD
)_-RRB-
3:21_CD
Page_NN NNCONC
9_CD
of_IN INother
11_CD
consider_VPRT MENTAL
these_DEMO
patients_NN NNHUMAN
as_IN INother
a_DT
high_JJAT JJATother
risk_NN NNABSPROC
group_NN NCOMP
based_VBN
on_IN INother
the_DT
cytogenetic_JJAT JJATother
classification_NN NOMZ
of_IN INother
AML_NN NNother
._.
Standard_JJAT JJREL
treatment_NN NNABSPROC
Standard_NN NNP
treatment_NN NCOMP
for_IN INother
paediatric_JJAT JJATother
patients_NN NNHUMAN
with_IN INother
AML_NN NNP
includes_VPRT EXIST
induction_NN NOMZ
chemotherapy_NN NCOMP
(_-LRB-
remission_NN NNother
induction_NN NCOMP
)_-RRB-
with_IN INother
an_DT
anthracycline_NN NNother
based_VBN
regimen_NN NNother
which_WHSC WHSCother
also_CC
contains_VPRT EXIST
cytarabine_NN NNother
._.
The_DT
choice_NN NNABSPROC
of_IN INother
the_DT
anthracycline_NN NNother
drug_NN NCOMP
used_VBN ACT
,_,
as_CC
well_RB RBother
as_IN INother
the_DT
total_JJAT JJATother
doses_NN NNother
of_IN INother
chemotherapy_NN NNother
differ_VPRT
between_IN INother
different_JJAT JJREL
centres_NN NNTECH
and_CC
collaborative_JJAT JJATother
study_NN NNABSPROC
groups_NN NCOMP
._.
Most_JJAT JJATother
children_NN NNHUMAN
achieve_VPRT
complete_JJAT JJREL
remission_NN NNother
with_IN INother
rates_NN NNQUANT
of_IN INother
80_CD
-_SYM
90_CD
%_NN NNother
after_IN INother
2_CD
induction_NN NOMZ
courses_NN NCOMP
and_CC
the_DT
toxic_JJAT JJATother
death_NN NNABSPROC
rate_NN NCOMP
is_VPRT BEMA
in_IN INother
the_DT
region_NN NNPLACE
of_IN INother
5_CD
%_NN NNother
,_,
with_IN INother
the_DT
failures_NN NSTNCother
being_VBG BEMA
due_IN INother
to_IN INother
resistant_JJAT JJATother
disease_NN NNother
[_-LRB-
4_CD
]_-RRB-
._.
Consolidation_NN NOMZ
or_CC
Intensification_NN NOMZ
chemotherapy_NN NCOMP
(_-LRB-
post_NN NNCONC
-_HYPH
remission_NN NNother
therapy_NN NCOMP
)_-RRB-
is_VPRT BEMA
essential_JJPR JJPRother
for_IN INother
cure_NN NNother
._.
It_PIT
includes_VPRT EXIST
the_DT
administration_NN NNABSPROC
of_IN INother
high_JJAT JJATother
dose_NN NNother
cytarabine_NN NCOMP
possibly_HDG
in_IN INother
combination_NN NNABSPROC
with_IN INother
other_JJAT JJATother
drugs_NN NNCONC
._.
Doses_NN NNother
,_,
duration_NN NOMZ
,_,
number_NN NNQUANT
of_IN INother
drugs_NN NNCONC
as_CC
well_RB RBother
as_IN INother
scheduling_NN NNother
differ_VPRT
between_IN INother
collaborative_JJAT JJATother
groups_NN NNother
._.
Currently_TIME
,_,
treatment_NN NNABSPROC
related_JJAT JJATother
death_NN NNABSPROC
rates_NN NCOMP
in_IN INother
AML_NN NNP
paediatric_JJAT JJATother
patients_NN NNHUMAN
,_,
with_IN INother
the_DT
improvement_NN NOMZ
of_IN INother
supportive_JJAT JJATother
care_NN NNABSPROC
and_CC
the_DT
administration_NN NNABSPROC
of_IN INother
treatment_NN NNABSPROC
in_IN INother
experienced_VBN MENTAL
units_NN NNTECH
,_,
are_VPRT BEMA
now_TIME
less_QUAN
than_IN INother
10_CD
%_NN NNother
[_-LRB-
4_CD
]_-RRB-
._.
Stem_NN NNCONC
cell_NN NCOMP
transplantation_NN NOMZ
Haematopoietic_JJAT JJATother
stem_NN NNCONC
cell_NN NCOMP
transplantation_NN NOMZ
(_-LRB-
HSCT_NN NNother
)_-RRB-
is_VPRT
considered_PASS PASSall MENTAL
an_DT
effective_JJAT JJATother
therapy_NN NNother
for_IN INother
treatment_NN NNABSPROC
of_IN INother
high_JJAT JJATother
risk_NN NNABSPROC
leukaemia_NN NCOMP
._.
However_CC
,_,
the_DT
high_JJAT JJATother
toxicity_NN NOMZ
which_WHSC WHSCother
includes_VPRT EXIST
a_DT
mortality_NN NOMZ
rate_NN NCOMP
reaching_VBG ACT
up_RP
to_IN INother
20_CD
%_NN NNother
in_IN INother
some_QUAN
series_NN NNABSPROC
,_,
makes_VPRT ACT
it_PIT
not_XX0
a_DT
standard_JJAT JJREL
therapy_NN NNother
in_IN INother
the_DT
first_JJAT JJATother
line_NN NNother
treatment_NN NCOMP
of_IN INother
AML_NN NNother
patients_NN NCOMP
with_IN INother
favourable_JJAT JJATother
cytogenetics_NN NNother
,_,
where_WHSC WHSCother
a_DT
high_JJAT JJATother
cure_NN NNother
rate_NN NCOMP
is_VPRT
achieved_PASS PASSall
with_IN INother
chemotherapy_NN NNother
alone_RB RBother
._.
For_IN INother
patients_NN NNHUMAN
with_IN INother
unfavourable_JJAT JJATother
cytogenetics_NN NNother
,_,
although_CONC
the_DT
benefit_NN NNABSPROC
of_IN INother
HSCT_NN NNP
is_VPRT BEMA
still_RB RBother
to_IN INother
be_VB SPLIT
fully_AMP
explored_PASS PASSall ACT
,_,
HSCT_NN NNP
is_VPRT
considered_PASS PASSall MENTAL
by_IN INother
many_QUAN
groups_NN NNother
as_IN INother
the_DT
standard_NN NNABSPROC
of_IN INother
care_NN NNABSPROC
[_-LRB-
57_CD
,_,
58_CD
]_-RRB-
._.
When_WHSC WHSCother
patients_NN NNHUMAN
relapse_VPRT
,_,
the_DT
most_RB SUPER
important_JJAT JJATother
prognostic_JJAT JJATother
factors_NN NNABSPROC
that_THRC THRCother
will_MDWS MDPREDall
determine_VB MENTAL
the_DT
outcome_NN NNother
of_IN INother
the_DT
salvage_NN NNother
therapy_NN NCOMP
are_VPRT BEMA
the_DT
length_NN NNQUANT
of_IN INother
first_JJAT JJATother
remission_NN NNother
and_CC
cytogenetics_NN NNother
._.
In_IN INother
the_DT
United_NN NNP
Kingdom_NN NNP
,_,
HSCT_NN NNP
is_VPRT SPLIT
generally_FREQ
used_PASS PASSall ACT
as_IN INother
consolidation_NN NOMZ
therapy_NN NCOMP
as_IN INother
part_NN NNQUANT
of_IN INother
salvage_NN NNother
treatment_NN NCOMP
with_IN INother
a_DT
survival_NN NNother
rate_NN NCOMP
of_IN INother
around_HDG
40_CD
%_NN NNother
achieved_VBN
irrespective_JJPR JJPRother
of_IN INother
the_DT
source_NN NNABSPROC
of_IN INother
stem_NN NNCONC
cells_NN NCOMP
._.
However_CC
,_,
it_PIT
is_VPRT BEMA
important_JJPR JJPRother
to_IN SPLIT
better_RB COMPAR
understand_VB MENTAL
molecular_NN NNother
markers_NN NCOMP
and_CC
cytogenetics_NN NNother
of_IN INother
the_DT
disease_NN NNother
to_IN INother
identify_VB MENTAL
patients_NN NNHUMAN
who_WHSC WHSCother
would_MDWO MDPREDall SPLIT
most_RB RBother
likely_RB RBother
benefit_VB
from_IN INother
this_DEMO
modality_NN NOMZ
of_IN INother
treatment_NN NNABSPROC
[_-LRB-
59_CD
]_-RRB-
._.
To_IN INother
date_NN NNQUANT
,_,
although_CONC
there_EX
are_VPRT
no_DMA
published_VBN
guidelines_NN NNother
about_IN INother
the_DT
management_NN NNABSPROC
of_IN INother
this_DEMO
group_NN NNother
,_,
there_EX
is_VPRT
increasing_PROG OCCUR
interest_NN NNABSPROC
among_IN INother
paediatric_JJAT JJATother
haematologists_NN NNother
/_,
study_NN NNABSPROC
groups_NN NCOMP
to_IN INother
consider_VB MENTAL
intensification_NN NOMZ
of_IN INother
therapy_NN NNother
with_IN INother
allogeneic_JJAT JJATother
stem_NN NNCONC
cell_NN NCOMP
transplantation_NN NOMZ
in_IN INother
first_JJAT JJATother
complete_JJAT JJREL
remission_NN NNother
[_-LRB-
13_CD
,_,
15_CD
,_,
16_CD
,_,
56_CD
]_-RRB-
._.
Further_JJAT COMPAR
study_NN NNABSPROC
of_IN INother
this_DEMO
important_JJAT JJATother
subgroup_NN NNother
of_IN INother
infant_NN NNHUMAN
AML_NN NCOMP
as_CC
well_RB RBother
as_IN INother
the_DT
incorporation_NN NOMZ
of_IN INother
t(_$
7;12_CD
)_-RRB-
in_IN INother
future_JJAT JJATother
risk_NN NNABSPROC
stratification_NN NCOMP
schemas_NN NNother
are_VPRT
needed_PASS PASSall MENTAL
to_IN SPLIT
better_RB COMPAR
understand_VB MENTAL
the_DT
best_JJAT SUPER
treatment_NN NNABSPROC
approach_NN NCOMP
._.
Conclusions_NN NSTNCother
The_DT
t(_NN NNother
7;12_CD
)_-RRB-
(_-LRB-
q36;p13_NN NNother
)_-RRB-
is_VPRT BEMA
a_DT
rare_JJAT JJATother
cytogenetic_JJAT JJATother
abnormality_NN NOMZ
in_IN INother
paediatric_JJAT JJATother
AML_NN NNother
and_CC
difficult_JJPR JJPRother
to_IN ToSTNCall ToJSTNCall ToJEASE
identify_VB MENTAL
using_VBG ACT
conventional_JJAT JJATother
karyotyping_NN NNother
._.
The_DT
use_NN NNABSPROC
of_IN INother
FISH_NN NNCONC
with_IN INother
appropriate_JJAT JJATother
probe_NN NNother
sets_NN NCOMP
would_MDWO MDPREDall
enable_VB CAUSE
diagnostic_JJAT JJATother
laboratories_NN NNGRP
to_IN INother
identify_VB MENTAL
this_DEMO
cytogenetic_JJAT JJATother
entity_NN NOMZ
confidently_RB RBother
and_CC
to_IN INother
give_VB ACT
a_DT
better_JJAT COMPAR
estimate_NN NNother
of_IN INother
its_PIT
occurrence_NN NNother
._.
The_DT
incidence_NN NNother
of_IN INother
t(_$
7;12_CD
)_-RRB-
leukaemias_NN NNother
is_VPRT BEMA
low_JJPR JJPRother
in_IN INother
overall_JJAT JJATother
paediatric_JJAT JJATother
AML_NN NNother
,_,
but_CC
significant_JJPR JJPRother
in_IN INother
infant_NN NNHUMAN
leukaemia_NN NCOMP
._.
There_EX
are_VPRT
no_DMA
published_VBN
management_NN NNABSPROC
guidelines_NN NCOMP
for_IN INother
those_DEMO
patients_NN NNHUMAN
,_,
but_CC
it_PIT
is_VPRT SPLIT
now_TIME
acknowledged_PASS PASSall COMM
as_IN INother
a_DT
high_JJAT JJATother
risk_NN NNABSPROC
group_NN NCOMP
with_IN INother
poor_JJAT JJEVAL
prognosis_NN NNother
and_CC
accordingly_RB RBother
many_QUAN
are_VPRT
being_PROG
treated_PASS PASSall
with_IN INother
HSCT_NN NNP
in_IN INother
first_JJAT JJATother
complete_JJAT JJREL
remission_NN NNother
._.
Better_JJAT COMPAR
understanding_NN NNCOG
of_IN INother
the_DT
genetic_JJAT JJATother
mechanisms_NN NNABSPROC
at_IN INother
the_DT
basis_NN NNother
of_IN INother
t(_$
7;12_CD
)_-RRB-
leukaemias_NN NNother
and_CC
the_DT
role_NN NNABSPROC
of_IN INother
HLXB9_NN NNother
in_IN INother
the_DT
establishment_NN NOMZ
of_IN INother
this_DEMO
malignancies_NN NNother
would_MDWO MDPREDall
provide_VB ACT
grounds_NN NNPLACE
for_IN PrepNSTNC
possible_JJPR JJEPSTother
tailored_VBN
therapy_NN NNother
._.